<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Enzyme Inhib Med Chem</journal-id><journal-title-group><journal-title>Journal of Enzyme Inhibition and Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">1475-6366</issn><issn pub-type="epub">1475-6374</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7744152</article-id><article-id pub-id-type="doi">10.1080/14756366.2020.1858820</article-id><article-id pub-id-type="publisher-id">1858820</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>New potent steroid sulphatase inhibitors based on 6-(1-phenyl-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate derivatives</article-title><alt-title alt-title-type="left-running-head">O. Ciupak et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ciupak</surname><given-names>Olga</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3367-6491</contrib-id><name><surname>Da&#x0015b;ko</surname><given-names>Mateusz</given-names></name><xref ref-type="aff" rid="AF0002">b</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3036-8693</contrib-id><name><surname>Biernacki</surname><given-names>Karol</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5377-8228</contrib-id><name><surname>Rachon</surname><given-names>Janusz</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Mas&#x00142;yk</surname><given-names>Maciej</given-names></name><xref ref-type="aff" rid="AF0003">c</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6870-845X</contrib-id><name><surname>Kubi&#x00144;ski</surname><given-names>Konrad</given-names></name><xref ref-type="aff" rid="AF0003">c</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7602-002X</contrib-id><name><surname>Martyna</surname><given-names>Aleksandra</given-names></name><xref ref-type="aff" rid="AF0003">c</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4252-4297</contrib-id><name><surname>Demkowicz</surname><given-names>Sebastian</given-names></name><xref ref-type="aff" rid="AF0001">a</xref><xref ref-type="corresp" rid="AN0001"/></contrib><aff id="AF0001"><label>a</label><institution>Department of Organic Chemistry, Faculty of Chemistry, Gda&#x00144;sk University of Technology</institution>, <city>Gda&#x00144;sk</city>, <country>Poland</country></aff><aff id="AF0002"><label>b</label><institution>Department of Inorganic Chemistry, Faculty of Chemistry, Gda&#x00144;sk University of Technology</institution>, <city>Gda&#x00144;sk</city>, <country>Poland</country></aff><aff id="AF0003"><label>c</label><institution>Department of Molecular Biology, The John Paul II Catholic University of Lublin</institution>, <city>Lublin</city>, <country>Poland</country></aff></contrib-group><author-notes><corresp id="AN0001">CONTACT Sebastian Demkowicz <email>sebastian.demkowicz@pg.edu.pl</email><addr-line><institution>Narutowicza</institution> 11/12</addr-line>, <postal-code>80-233</postal-code><city>Gdansk</city>, <country>Poland</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>15</day><month>12</month><year>2020</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2021</year></pub-date><volume>36</volume><issue>1</issue><fpage seq="23">238</fpage><lpage>247</lpage><permissions><copyright-statement>&#x000a9; 2020 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IENZ_36_1858820.pdf"/><abstract><title>Abstract</title><p>In the present work, we report a new class of potent steroid sulphatase (STS) inhibitors based on 6-(1-phenyl-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate derivatives. Within the set of new STS inhibitors, 6-(1-(1,2,3-trifluorophenyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate <bold>3L</bold> demonstrated the highest activity in the enzymatic assay inhibiting the STS activity to 7.98% at 0.5&#x02009;&#x000b5;M concentration. Furthermore, to verify whether the obtained STS inhibitors are able to pass through the cellular membrane effectively, cell line experiments have been carried out. We found that the lowest STS activities were measured in the presence of compound <bold>3L</bold> (remaining STS activity of 5.22%, 27.48% and 99.0% at 100, 10 and 1&#x02009;nM concentrations, respectively). The measured STS activities for <italic>Irosustat</italic> (used as a reference) were 5.72%, 12.93% and 16.83% in the same concentration range. Moreover, a determined IC<sub>50</sub> value of 15.97&#x02009;nM for <bold>3L</bold> showed that this compound is a very promising candidate for further preclinical investigations.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Steroid sulphatase</kwd><kwd>hormone-dependent cancer</kwd><kwd>breast cancer</kwd><kwd>STS inhibitors</kwd><kwd>triazoles</kwd></kwd-group><counts><fig-count count="1"/><table-count count="4"/><page-count count="10"/><word-count count="8500"/></counts></article-meta></front><body><sec sec-type="intro" id="S0001" disp-level="1"><title>Introduction</title><p>Cancer is the second leading cause of death worldwide. As reported by <italic>International Agency for Research on Cancer</italic>, there were more than 18 million new cases diagnosed and 9.5 million tumour-related deaths in 2018 worldwide<xref rid="CIT0001" ref-type="bibr"><sup>1</sup></xref>. The most common types of cancer are lung, breast, colorectal, prostate, and stomach, which constitute almost 50% of all tumour cases. Moreover, lung, colorectal, stomach, liver, and breast cancers are responsible for nearly 50% of all deaths. <italic>National Cancer Institute</italic> estimates that more than 270&#x02009;000 (15.3%) new cases of breast cancer will be diagnosed and more than 42&#x02009;000 (7.0%) deaths will be reported of this disease in the United States of America in 2020<xref rid="CIT0002" ref-type="bibr"><sup>2</sup></xref>. Approximately 95% of breast cancer cases in the primary stage are hormone-sensitive, and therefore, biological active hormones (including oestrogens and androgens) play a crucial role in the proliferation of tumours cells<xref rid="CIT0003" ref-type="bibr"><sup>3</sup></xref>. The biosynthesis of active steroids in cancer tissues mainly depends on the following three enzymatic pathways: aromatase (responsible for the transformation of androgens into oestrogens), 17&#x003b2;-hydroxysteroid dehydrogenase (implicated in the reduction of oestrone to oestradiol) and steroid sulphatase (STS). STS acts by hydrolysing steroid sulphates (including oestrone sulphate and dehydroepiandrosterone sulphate) and therefore plays a pivotal role in human steroidogenesis process<xref rid="CIT0004" ref-type="bibr"><sup>4&#x02013;7</sup></xref>. Current breast cancer therapies are based on chemotherapeutics that act as selective oestrogen receptor modulators (SERMs) (e.g. <italic>Tamoxifen</italic>) or inhibitors of the aromatase enzyme complex (e.g. <italic>Letrozole</italic> or <italic>Anastrozole</italic>)<xref rid="CIT0008" ref-type="bibr"><sup>8&#x02013;10</sup></xref>. Unfortunately, both methods of treatment are unsatisfactory. The main reason for the failure of the therapy based on aromatase inhibitors is the fact that aromatase expression is significantly lower than STS<xref rid="CIT0011" ref-type="bibr"><sup>11</sup></xref>. Furthermore, there are studies demonstrating a significant increment of STS and 17&#x003b2;-HSD1 following aromatase inhibitor therapy of ER positive postmenopausal breast carcinoma patients due to the compensatory response of breast carcinoma tissues to oestrogen depletion<xref rid="CIT0012" ref-type="bibr"><sup>12</sup></xref>.</p><p>Nowadays, STS has been considered as an attractive molecular target for the development of hormone-dependent cancer therapies, and therefore, the synthesis of new, efficient, selective STS inhibitors is of particular importance for modern medicinal chemistry. Recently, there has been intensive research towards finding novel STS inhibitors. Scientists have developed, both, steroidal and non-steroidal compounds containing various functional groups (e.g. sulphamate and phosphorus moieties)<xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref>. For example, one of the most promising drug candidate based on a sulphamoylated coumarin core is <italic>Irosustat</italic> (also known as 667-COUMATE or STX64). <italic>Irosustat</italic> is in clinical trials (phase II clinical studies) and exhibits quite good results towards treating hormone-dependent breast cancer (without having <italic>in&#x000a0;vivo</italic> and <italic>in&#x000a0;vitro</italic> oestrogenic properties)<xref rid="CIT0014" ref-type="bibr"><sup>14&#x02013;20</sup></xref>. Although <italic>Irosustat</italic> showed very promising clinical effects in the treatment of hormone-dependent tumours, in relation to endometrium (where occurs high STS activity) <italic>Irosustat</italic> did not demonstrate activity sufficient for future commercial development<xref rid="CIT0021" ref-type="bibr"><sup>21</sup></xref>. For this reason, the search for more effective STS inhibitors is still ongoing.</p><p>In the present work, we described our recent research on the design, synthesis, and biological evaluation of compounds based on non-steroidal core containing triazole and naphthalene rings in their structure as new and potent STS inhibitors. The presence of the triazole ring in the structure of obtained compounds is justified by the fact that triazoles are a class of compounds showing very attractive properties and are successfully used in the design of new pharmaceuticals<xref rid="CIT0022" ref-type="bibr"><sup>22</sup></xref>. One of the most important triazoles feature is that they do not undergo hydrolysis under acidic, basic, and redox conditions and they are stable to metabolic degradation. Moreover, these compounds are weakly acidic and weakly basic. Some properties like hydrogen bond formation, &#x003c0;-&#x003c0; stacking interaction, strong dipole moments, and bioisosteric effects make triazole derivatives an attractive type of compounds in the field of medicinal chemistry. Despite the fact that 1,2,3-triazoles do not exist in the nature<xref rid="CIT0023" ref-type="bibr"><sup>23</sup></xref> such compounds exhibit many biological activities (e.g. anticancer<xref rid="CIT0024" ref-type="bibr"><sup>24</sup></xref><sup>,</sup><xref rid="CIT0025" ref-type="bibr"><sup>25</sup></xref>, antimicrobial<xref rid="CIT0026" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="CIT0027" ref-type="bibr"><sup>27</sup></xref>, anti-infective<xref rid="CIT0028" ref-type="bibr"><sup>28</sup></xref>).</p></sec><sec sec-type="materials" id="S0002" disp-level="1"><title>Materials and methods</title><sec id="S0002-S2001" disp-level="2"><title>General methods and materials</title><p>6-Bromo-2-naphthol, trimethylsilylacetylene, palladium(II) chloride, triphenylphosphine, copper(I) iodide, triethylamine, the appropriate aniline derivatives, <italic>tert</italic>-butyl nitrite (<italic>t</italic>-BuONO), azidotrimethylsilane (TMSN<sub>3</sub>), 1&#x02009;M solution of tetrabutylammonium fluoride (TBAF) in tetrahydrofuran (THF), sodium ascorbate, copper(II) sulphate pentahydrate, chlorosulphonyl isocyanate, <italic>N</italic>,<italic>N</italic>-dimethylacetamide (<italic>N</italic>,<italic>N</italic>-DMA), and formic acid were commercially available from Sigma-Aldrich. Radiolabelled [<sup>3</sup>H] oestrone sulphate for enzyme and cellular assays was purchased from PerkinElmer. Acetonitrile (ACN) and dichloromethane (DCM) were dried and distilled using standard procedures. Melting points (uncorrected) were determined with a Stuart Scientific SMP30 apparatus. Infra-red spectra were measured on a Nicolet 8700 spectrometer. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker Avance III HD 400&#x02009;MHz spectrometer. Chemical shifts &#x003b4; are reported in parts per million relative to the residual solvent peak (CDCl<sub>3</sub> = 7.26&#x02009;ppm for <sup>1</sup>H, 77.0&#x02009;ppm for <sup>13</sup>C, DMSO-d<sub>6</sub> 2.49&#x02009;ppm for <sup>1</sup>H, and 39.5&#x02009;ppm for <sup>13</sup>C). Coupling constants are given in Hertz. Mass spectra were recorded on an Agilent 6540 Accurate Mass Q-TOF LC/MS System. Elemental analysis was performed using CHNS-Carlo Erba EA-1108. Preparative thin-layer chromatography (TLC) was carried out with Polygram SIL G/UV254, silica gel (Macherey-Nagel GmbH &#x00026; Co. KG, D&#x000fc;ren, Germany). Column chromatography was performed using silica gel 60 (230-400 mesh, Merck).</p><sec id="S0002-S2001-S3001" disp-level="3"><title>General method for the synthesis of 6-((trimethylsilyl)ethynyl)naphthalen-2-ol 1</title><p>A solution of 6-bromo-2-naphthol (892&#x02009;mg, 4&#x02009;mmol), trimethylsilylacetylene (0.831&#x02009;ml, 6&#x02009;mmol), palladium(II) chloride (35.5&#x02009;mg, 0.20&#x02009;mmol), triphenylphosphine (105&#x02009;mg, 0.40&#x02009;mmol), copper(I) iodide (19&#x02009;mg, 0.10&#x02009;mmol) and triethylamine (3.94&#x02009;ml, 28.2&#x02009;mmol) in dry ACN (20&#x02009;ml) was refluxed under an argon atmosphere. After 3&#x02009;h of heating, the reaction mixture was cooled down and filtered. The filtrate was concentrated under reduced pressure and crude product was purified with column chromatography using AcOEt/hexane (1:4) as eluent to afford the desired compound <bold>1</bold>.</p><p><bold>6-((Trimethylsilyl)ethynyl)naphthalen-2-ol 1</bold> Yield 68%; mp 92-94&#x02009;&#x000b0;C; &#x003bd;<sub>max</sub> (KBr)/cm<sup>&#x02212;1</sup> 3245, 2166, 1602, 1506, 1248, 941, 836, 703; <sup>1</sup>H NMR &#x003b4;<sub>H</sub> (400&#x02009;MHz, CDCl<sub>3</sub>) 7.96 (1H, s, Ar-H), 7.73-7.70 (1H, m, Ar-H), 7.61 (1H, d, <italic>J</italic>&#x02009;=&#x02009;8.5&#x02009;Hz, Ar-H), 7.49 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.5, 1.6&#x02009;Hz, Ar-H), 7.14-7.11 (2H, m, Ar-H), 5.55-4.53 (1H, brs, OH) 0.31 (9H, s, CH<sub>3</sub>); <sup>13</sup>C NMR &#x003b4;<sub>C</sub> (101&#x02009;MHz, CDCl<sub>3</sub>) 154.1, 134.2, 132.0, 129.9, 129.3, 128.3, 126.3, 118.4, 118.1, 109.6, 105.7, 93.8, 0.1; Anal. calcd for: C<sub>15</sub>H<sub>16</sub>OSi, C, 74.95; H, 6.71; O, 6.66; Si, 11.68. Found: C, 74.90; H, 6.75; O, 6.70; Si, 11.68%. HRMS (m/z) [M&#x02014;H]<sup>&#x02013;</sup> calcd 239.1155, found 239.0897.</p></sec><sec id="S0002-S2001-S3002" disp-level="3"><title>General method for the synthesis of 6&#x02013;(1-phenyl-1H-1,2,3-triazol-4-yl)naphthalen-2-ol derivatives 2&#x02009;A-L</title><p>To an ice-cooled solution of corresponding amine (2.63&#x02009;mmol) in ACN (6.1&#x02009;ml), <italic>t</italic>-BuONO (325&#x02009;mg, 3.16&#x02009;mmol) was added dropwise, followed by TMSN<sub>3</sub> (333&#x02009;mg, 2.89&#x02009;mmol). Solution was stirred at room temperature for 4&#x02009;h and in the next step, <bold>1</bold> (632&#x02009;mg, 2.63&#x02009;mmol) and 1&#x02009;M solution of TBAF in THF (2.89&#x02009;ml) were added. The reaction mixture was stirred at 0&#x02009;&#x000b0;C for 30&#x02009;min. Subsequently, CuSO<sub>4</sub> &#x000b7; 5H<sub>2</sub>O (65.7&#x02009;mg, 0.263&#x02009;mmol) and a freshly prepared aqueous solution (0.526&#x02009;ml) of sodium ascorbate (104&#x02009;mg, 0.526&#x02009;mmol) were added, and the obtained solution was stirred for 24&#x02009;h under an argon atmosphere at room temperature. Afterwards, the reaction mixture was concentrated under vacuum and the crude product was dissolved in AcOEt (30&#x02009;ml). Obtained solution was washed with 0.1&#x02009;M hydrochloric acid. After separation organic phase was dried using MgSO<sub>4</sub>, solvent was evaporated and the resulting residue was crystallised from ACN to give the desired products <bold>2&#x02009;A-L</bold>.</p><p><bold>6-(1-Phenyl-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-ol 2A</bold> Yield 64%; mp (with decomposition) 228-230&#x02009;&#x000b0;C; &#x003bd;<sub>max</sub> (KBr)/cm<sup>&#x02212;1</sup> 3293, 3137, 1598, 1504, 1228, 1036, 871, 683; <sup>1</sup>H NMR &#x003b4;<sub>H</sub> (400&#x02009;MHz, DMSO-d<sub>6</sub>) 9.87 (1H, s, OH), 9.35 (1H, s, CH), 8.39 (1H, s, Ar-H), 8.02-7.96 (3H, m, Ar-H), 7.86 (1H, d, <italic>J</italic>&#x02009;=&#x02009;8.8&#x02009;Hz, Ar-H), 7.82 (1H, d, <italic>J</italic>&#x02009;=&#x02009;8.7&#x02009;Hz, Ar-H), 7.65 (2H, t, <italic>J</italic>&#x02009;=&#x02009;7.9&#x02009;Hz, Ar-H), 7.53 (1H, t, <italic>J</italic>&#x02009;=&#x02009;7.4&#x02009;Hz, Ar-H), 7.18 (1H, d, <italic>J</italic>&#x02009;=&#x02009;2.3&#x02009;Hz, Ar-H), 7.15 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.7, 2.4&#x02009;Hz, Ar-H); <sup>13</sup>C NMR &#x003b4;<sub>C</sub> (101&#x02009;MHz, DMSO-d<sub>6</sub>) 156.2, 148.2, 137.2, 134.9, 130.4, 130.2, 129.1, 128.2, 127.3, 125.0, 124.4, 124.3, 120.4, 119.8, 119.7, 109.3; Anal. calcd for: C<sub>18</sub>H<sub>13</sub>N<sub>3</sub>O, C, 75.25; H, 4.56; N, 14.63; O, 5.57. Found: C, 75.31; H, 4.49; N, 14.71; O, 5.49%. HRMS (m/z) [M&#x02009;+&#x02009;H]<sup>+</sup> calcd 288.1132, found 288.3504.</p><p><bold>6-(1-(3-Fluorophenyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-ol 2B</bold> Yield 43%; mp (with decomposition) 219-220&#x02009;&#x000b0;C; &#x003bd;<sub>max</sub> (KBr)/cm<sup>&#x02212;1</sup> 3251, 3125, 2352, 1600, 1498, 1231, 1033, 870, 677; <sup>1</sup>H NMR &#x003b4;<sub>H</sub> (400&#x02009;MHz, DMSO-d<sub>6</sub>) 9.88 (1H, s, OH), 9.40 (1H, s, CH), 8.37 (1H, s, Ar-H), 7.95 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.5, 1.7&#x02009;Hz, Ar-H), 7.93-7.80 (4H, m, Ar-H), 7.70 (1H, td, <italic>J</italic>&#x02009;=&#x02009;8.3, 6.5&#x02009;Hz, Ar-H), 7.38 (1H, tdd, <italic>J</italic>&#x02009;=&#x02009;8.5, 2.5, 0.7&#x02009;Hz, Ar-H), 7.18 (1H, d, <italic>J</italic>&#x02009;=&#x02009;2.1&#x02009;Hz, Ar-H), 7.15 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.7, 2.4&#x02009;Hz, Ar-H); <sup>13</sup>C NMR &#x003b4;<sub>C</sub> (101&#x02009;MHz, DMSO-d<sub>6</sub>) 162.9 (d, <sup>1</sup><italic>J</italic><sub>C-F</sub> = 245.1&#x02009;Hz), 156.3, 148.3, 138.4 (d, <sup>3</sup><italic>J</italic><sub>C-F</sub> = 10.5&#x02009;Hz), 134.9, 132.4 (d, <sup>3</sup><italic>J</italic><sub>C-F</sub> = 9.2&#x02009;Hz), 130.2, 128.1, 127.3, 124.8, 124.3, 119.9, 119.8, 116.3 (d, <sup>4</sup><italic>J</italic><sub>C-F</sub> = 3.0&#x02009;Hz), 115.8 (d, <sup>2</sup><italic>J</italic><sub>C-F</sub> = 21.0&#x02009;Hz), 109.3, 107.9 (d, <sup>2</sup><italic>J</italic><sub>C-F</sub> = 26.5&#x02009;Hz); Anal. calcd for: C<sub>18</sub>H<sub>12</sub>FN<sub>3</sub>O, C, 70.81; H, 3.96; F, 6.22; N, 13.76; O, 5.24. Found: C, 70.79; H, 3.99; F, 6.24; N, 13.69; O, 5.29%. HRMS (m/z) [M&#x02009;+&#x02009;H]<sup>+</sup> calcd 306.1038, found 306.3540.</p><p><bold>6-(1-(3-Chlorophenyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-ol 2C</bold> Yield 45%; mp (with decomposition) 229-231&#x02009;&#x000b0;C; &#x003bd;<sub>max</sub> (KBr)/cm<sup>&#x02212;1</sup> 3254, 3129, 2345, 1598, 1221, 1035, 869, 679; <sup>1</sup>H NMR &#x003b4;<sub>H</sub> (400&#x02009;MHz, DMSO-d<sub>6</sub>) 9.88 (1H, s, OH), 9.43 (1H, s, CH), 8.37 (1H, s, Ar-H), 8.12 (1H, t, <italic>J</italic>&#x02009;=&#x02009;2.0&#x02009;Hz, Ar-H), 8.01 (1H, ddd, <italic>J</italic>&#x02009;=&#x02009;8.1, 2.0, 0.9&#x02009;Hz, Ar-H), 7.95 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.5, 1.7&#x02009;Hz, Ar-H), 7.86 (1H, d, <italic>J</italic>&#x02009;=&#x02009;8.8&#x02009;Hz, Ar-H), 7.82 (1H, d, <italic>J</italic>&#x02009;=&#x02009;8.6&#x02009;Hz, Ar-H) 7.68 (1H, t, <italic>J</italic>&#x02009;=&#x02009;8.1&#x02009;Hz, Ar-H), 7.59 (1H, ddd, <italic>J</italic>&#x02009;=&#x02009;8.1, 1.9, 0.9&#x02009;Hz, Ar-H), 7.19-7.17 (1H, m, Ar-H), 7.15 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.7, 2.4&#x02009;Hz, Ar-H); <sup>13</sup>C NMR &#x003b4;<sub>C</sub> (101&#x02009;MHz, DMSO-d<sub>6</sub>) 156.3, 148.3, 138.2, 134.9, 134.7, 132.2, 130.2, 128.9, 128.1, 127.3, 124.8, 124.3, 120.2, 119.9, 119.8, 118.9, 109.3; Anal. calcd for: C<sub>18</sub>H<sub>12</sub>ClN<sub>3</sub>O, C, 67.19; H, 3.76; Cl, 11.02; N, 13.06; O, 4.97. Found: C, 67.09; H, 3.84; Cl, 11.09; N, 12.99; O, 4.99%. HRMS (m/z) [M&#x02009;+&#x02009;H]<sup>+</sup> calcd 321.0669, found 322.3397.</p><p><bold>6-(1-(3-Bromophenyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-ol 2D</bold> Yield 42%; mp (with decomposition) 226-228&#x02009;&#x000b0;C; &#x003bd;<sub>max</sub> (KBr)/cm<sup>&#x02212;1</sup> 3271, 3130, 2922, 2350, 1583, 1489, 1034, 782; <sup>1</sup>H NMR &#x003b4;<sub>H</sub> (400&#x02009;MHz, DMSO-d<sub>6</sub>) 9.88 (1H, s, OH), 9.43 (1H, s, CH), 8.37 (1H, s, Ar-H), 8.24 (1H, s, Ar-H), 8.04 (1H, d, <italic>J</italic>&#x02009;=&#x02009;8.1&#x02009;Hz, Ar-H), 7.95 (1H, d, <italic>J</italic>&#x02009;=&#x02009;8.2&#x02009;Hz, Ar-H), 7.86 (1H, d, <italic>J</italic>&#x02009;=&#x02009;8.8&#x02009;Hz, Ar-H), 7.82 (1H, d, <italic>J</italic>&#x02009;=&#x02009;8.6&#x02009;Hz, Ar-H), 7.72 (1H, d, <italic>J</italic>&#x02009;=&#x02009;7.8&#x02009;Hz, Ar-H), 7.61 (1H, t, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz, Ar-H), 7.18 (1H, s, Ar-H), 7.15 (1H, d, <italic>J</italic>&#x02009;=&#x02009;8.9&#x02009;Hz, Ar-H); <sup>13</sup>C NMR &#x003b4;<sub>C</sub> (101&#x02009;MHz, DMSO-d<sub>6</sub>) 156.3, 148.3, 138.3, 134.9, 132.4, 131.8, 130.2, 128.1, 127.3, 124.8, 124.3, 123.0, 122.9, 119.9, 119.8, 119.3, 109.3; Anal. calcd for: C<sub>18</sub>H<sub>12</sub>BrN<sub>3</sub>O, C, 59.03; H, 3.30; Br, 21.82; N, 11.47; O, 4.37. Found: C, 59.11; H, 3.28; Br, 21.87; N, 11.50; O, 4.24%. HRMS (m/z) [M&#x02009;+&#x02009;H]<sup>+</sup> calcd 366.0237, found 366.3458.</p><p><bold>6-(1-(4-Fluorophenyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-ol 2E</bold> Yield 74%; mp (with decomposition) 237-239&#x02009;&#x000b0;C; &#x003bd;<sub>max</sub> (KBr)/cm<sup>&#x02212;1</sup> 3651, 3199, 3124, 2920, 2347, 1614, 1507, 1039, 802; <sup>1</sup>H NMR &#x003b4;<sub>H</sub> (400&#x02009;MHz, DMSO-d<sub>6</sub>) 9.86 (1H, s, OH), 9.33 (1H, s, CH), 8.37 (1H, s, Ar-H), 8.06-8.00 (2H, m, Ar-H), 7.96 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.5, 1.5&#x02009;Hz, Ar-H), 7.86 (1H, d, <italic>J</italic>&#x02009;=&#x02009;8.8&#x02009;Hz, Ar-H), 7.82 (1H, d, <italic>J</italic>&#x02009;=&#x02009;8.6&#x02009;Hz, Ar-H), 7.52 (2H, t, <italic>J</italic>&#x02009;=&#x02009;8.8&#x02009;Hz, Ar-H), 7.17 (1H, s, Ar-H), 7.15 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.8, 2.3&#x02009;Hz, Ar-H); <sup>13</sup>C NMR &#x003b4;<sub>C</sub> (101&#x02009;MHz, DMSO-d<sub>6</sub>) 162.1 (d, <sup>1</sup>J<sub>C-F</sub> = 245.8&#x02009;Hz), 156.2, 148.2, 134.9, 133.8 (d, <sup>4</sup>J<sub>C-F</sub> = 2.8&#x02009;Hz), 130.1, 128.2, 127.3, 125.0, 124.4, 124.2, 122.8 (d, <sup>3</sup>J<sub>C-F</sub> = 8.8&#x02009;Hz), 120.0, 119.8, 117.3 (d, <sup>2</sup>J<sub>C-F</sub> = 23.3&#x02009;Hz), 109.2; Anal. calcd for: C<sub>18</sub>H<sub>12</sub>FN<sub>3</sub>O, C, 70.81; H, 3.96; F, 6.22; N, 13.76; O, 5.24. Found: C, 70.75; H, 3.99; F, 6.27; N, 13.81; O, 5.18%. HRMS (m/z) [M&#x02009;+&#x02009;H]<sup>+</sup> calcd 306.1038, found 306.3524.</p><p><bold>6-(1-(4-Chlorophenyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-ol 2F</bold> Yield 74%; mp (with decomposition) 256-257&#x02009;&#x000b0;C; &#x003bd;<sub>max</sub> (KBr)/cm<sup>&#x02212;1</sup> 3286, 3119, 2294, 1611, 1550, 1032, 831; <sup>1</sup>H NMR &#x003b4;<sub>H</sub> (400&#x02009;MHz, DMSO-d<sub>6</sub>) 9.86 (1H, s, OH), 9.38 (1H, s, CH), 8.37 (1H, s, Ar-H) 8.03 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8.9&#x02009;Hz, Ar-H), 7.95 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.5, 1.6&#x02009;Hz, Ar-H), 7.86 (1H, d, <italic>J</italic>&#x02009;=&#x02009;8.8&#x02009;Hz, Ar-H), 7.82 (1H, d, <italic>J</italic>&#x02009;=&#x02009;8.6&#x02009;Hz, Ar-H), 7.73 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8.9&#x02009;Hz, Ar-H), 7.17 (1H, s, Ar-H), 7.15 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.7, 2.3&#x02009;Hz, Ar-H); <sup>13</sup>C NMR &#x003b4;<sub>C</sub> (101&#x02009;MHz, DMSO-d<sub>6</sub>) 156.3, 148.3, 136.0, 134.9, 133.4, 130.4, 130.2, 128.2, 127.3, 124.9, 124.4, 124.3, 122.1, 119.8, 109.3; Anal. calcd for: C<sub>18</sub>H<sub>12</sub>ClN<sub>3</sub>O, C, 67.19; H, 3.76; Cl, 11.02; N, 13.06; O, 4.97. Found: C, 67.24; H, 3.69; Cl, 11.09; N, 13.04; O, 4.49%. HRMS (m/z) [M&#x02009;+&#x02009;H]<sup>+</sup> calcd 322.0742, found 322.3345.</p><p><bold>6-(1-(4-Bromophenyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-ol 2G</bold> Yield 62%; mp (with decomposition) 254-256&#x02009;&#x000b0;C; &#x003bd;<sub>max</sub> (KBr)/cm<sup>&#x02212;1</sup> 3470, 3119, 1612, 1495, 1200, 1030, 867, 810; <sup>1</sup>H NMR &#x003b4;<sub>H</sub> (400&#x02009;MHz, DMSO-d<sub>6</sub>) 9.86 (1H, s, OH), 9.38 (1H, s, CH), 8.37 (1H, s, Ar-H), 7.99-7.93 (3H, m, Ar-H), 7.88-7.80 (4H, m, Ar-H), 7.17 (1H, s, Ar-H), 7.15 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.7, 2.4&#x02009;Hz, Ar-H); <sup>13</sup>C NMR &#x003b4;<sub>C</sub> (101&#x02009;MHz, DMSO-d<sub>6</sub>) 156.3, 148.3, 136.4, 134.9, 133.3, 130.2, 128.1, 127.3, 124.9, 124.4, 124.3, 122.3, 121.7, 119.8, 119.7, 109.3; Anal. calcd for: C<sub>18</sub>H<sub>12</sub>BrN<sub>3</sub>O, C, 59.03; H, 3.30; Br, 21.82; N, 11.47; O, 4.37. Found: C, 59.07; H, 3.32; Br, 21.78; N, 11.54; O, 4.29%. HRMS (m/z) [M&#x02009;+&#x02009;H]<sup>+</sup> calcd 366.0237, found 366.3154.</p><p><bold>6-(1-(2-Fluorophenyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-ol 2H</bold> Yield 47%; mp (with decomposition) 207-208&#x02009;&#x000b0;C; &#x003bd;<sub>max</sub> (KBr)/cm<sup>&#x02212;1</sup> 3177, 1614, 1511, 1048, 864, 819; <sup>1</sup>H NMR &#x003b4;<sub>H</sub> (400&#x02009;MHz, DMSO-d<sub>6</sub>) 9.86 (1H, s, OH), 9.12 (1H, d, <italic>J</italic>&#x02009;=&#x02009;1.9&#x02009;Hz, CH), 8.41 (1H, s, Ar-H), 8.02-7.91 (2H, m, Ar-H), 7.83 (2H, dd, <italic>J</italic>&#x02009;=&#x02009;20.5, 8.7&#x02009;Hz, Ar-H), 7.68-7.58 (2H, m, Ar-H), 7.54-7.45 (1H, m, Ar-H), 7.19-7.09 (2H, m, Ar-H); <sup>13</sup>C NMR &#x003b4;<sub>C</sub> (101&#x02009;MHz, DMSO-d<sub>6</sub>) 156.3, 154.3 (d, <sup>1</sup><italic>J</italic><sub>C-F</sub> = 250.8&#x02009;Hz), 147.8, 134.8, 131.8 (d,</p><p><sup>2</sup><italic>J</italic><sub>C-F</sub> = 7.8&#x02009;Hz), 130.2, 128.2, 127.3, 126.5, 126.1 (d, <sup>3</sup><italic>J</italic><sub>C-F</sub> = 3.7&#x02009;Hz), 125.3 (d, <sup>2</sup><italic>J</italic><sub>C-F</sub> = 11.0&#x02009;Hz), 124.8, 124.4, 122.9 (d, <sup>3</sup><italic>J</italic><sub>C-F</sub> = 4.1&#x02009;Hz), 119.8, 117.8, 117.6, 108.9; Anal. calcd for: C<sub>18</sub>H<sub>12</sub>FN<sub>3</sub>O, C, 70.81; H, 3.96; F, 6.22; N, 13.76; O, 5.24. Found: C, 70.78; H, 3.99; F, 6.28; N, 13.70; O, 5.25%. HRMS (m/z) [M&#x02009;+&#x02009;H]<sup>+</sup> calcd 306.1038, found 306.3529.</p><p><bold>6-(1-(2-Chlorophenyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-ol 2I</bold> Yield 62%; mp 104-106&#x02009;&#x000b0;C; &#x003bd;<sub>max</sub> (KBr)/cm<sup>&#x02212;1</sup> 3133, 1616, 1493, 1493, 1196, 1050, 862, 804; <sup>1</sup>H NMR &#x003b4;<sub>H</sub> (400&#x02009;MHz, DMSO-d<sub>6</sub>) 9.86 (1H, s, OH), 9.08 (1H, s, CH), 8.39 (1H, s, Ar-H), 7.96 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.5, 1.6&#x02009;Hz, Ar-H), 7.90-7.75 (4H, m, Ar-H), 7.73&#x02013;7.59 (2H, m, Ar-H), 7.21-7.11 (2H, m, Ar-H); <sup>13</sup>C NMR &#x003b4;<sub>C</sub> (101&#x02009;MHz, DMSO-d<sub>6</sub>) 156.3, 147.4, 135.1, 134.9, 132.2, 131.1, 130.2, 129.0, 128.9, 128.8, 128.2, 127.3, 124.9, 124.4, 124.3, 123.7, 119.8, 109.3; Anal. calcd for: C<sub>18</sub>H<sub>12</sub>ClN<sub>3</sub>O, C, 67.19; H, 3.76; Cl, 11.02; N, 13.06; O, 4.97. Found: C, 67.22; H, 3.70; Cl, 11.08; N, 13.11; O, 4.89%. HRMS (m/z) [M&#x02009;+&#x02009;H]<sup>+</sup> calcd 322.0742, found 322.3377.</p><p><bold>6-(1-(2-Bromophenyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-ol 2J</bold> Yield 68%; mp 105-107&#x02009;&#x000b0;C; &#x003bd;<sub>max</sub> (KBr)/cm<sup>&#x02212;1</sup> 3135, 1611, 1493, 1283, 1048, 909; <sup>1</sup>H NMR &#x003b4;<sub>H</sub> (400&#x02009;MHz, DMSO-d<sub>6</sub>) 9.86 (1H, s, OH), 9.05 (1H, s, CH), 8.39 (1H, s, Ar-H), 7.97-7.95 (2H, m, Ar-H), 7.83 (2H, dd, <italic>J</italic>&#x02009;=&#x02009;18.6, 8.7&#x02009;Hz, Ar-H), 7.77 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;7.8, 1.6&#x02009;Hz), 7.67 (1H, td, <italic>J</italic>&#x02009;=&#x02009;7.7, 1.4&#x02009;Hz, Ar-H), 7.60 (1H, td, <italic>J</italic>&#x02009;=&#x02009;7.7, 1.4&#x02009;Hz, Ar-H), 7.21-7.18 (1H, m, Ar-H), 7.14 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.8, 2.4&#x02009;Hz, Ar-H); <sup>13</sup>C NMR &#x003b4;<sub>C</sub> (101&#x02009;MHz, DMSO-d<sub>6</sub>) 156.2, 147.3, 136.8, 134.9, 134.2, 132.5, 130.2, 129.5, 129.2, 128.2, 127.3, 125.0, 124.4, 124.3, 123.7, 119.8, 119.4, 109.3; Anal. calcd for: C<sub>18</sub>H<sub>12</sub>BrN<sub>3</sub>O, C, 59.03; H, 3.30; Br, 21.82; N, 11.47; O, 4.37. Found: C, 59.10; H, 3.26; Br, 21.86; N, 11.36; O, 4,42%. HRMS (m/z) [M&#x02009;+&#x02009;H]<sup>+</sup> calcd 366.0237, found 366.3130.</p><p><bold>6-(1-(3,5-Difluorophenyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-ol 2K</bold> Yield 39%; mp (with decomposition) 210-212&#x02009;&#x000b0;C; &#x003bd;<sub>max</sub> (KBr)/cm<sup>&#x02212;1</sup> 3128, 1607, 1482, 1303, 1050, 911; <sup>1</sup>H NMR &#x003b4;<sub>H</sub> (400&#x02009;MHz, DMSO-d<sub>6</sub>) 9.88 (1H, s, OH), 9.43 (1H, s, CH), 8.35 (1H, s, Ar-H), 7.95-7.80 (4H, m, Ar-H), 7.46 (1H, tt, <italic>J</italic>&#x02009;=&#x02009;9.2, 2.2&#x02009;Hz, Ar-H), 7.20-7.17 (2H, m, Ar-H), 7.15 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.7, 2.4&#x02009;Hz, Ar-H); <sup>13</sup>C NMR &#x003b4;<sub>C</sub> (101&#x02009;MHz, DMSO-d<sub>6</sub>) 163.2 (dd, <sup>1</sup><italic>J</italic><sub>C-F</sub> = 246.9, <sup>3</sup><italic>J</italic><sub>C-F</sub> = 14.6&#x02009;Hz), 156.4, 148.4, 138.9 (t, <sup>3</sup><italic>J</italic><sub>C-F</sub> = 13.3&#x02009;Hz), 135.0, 130.2, 128.1, 127.4, 124.6, 124.4, 124.2, 120.0, 119.9, 109.3, 104.4, 104; Anal. calcd for: C<sub>18</sub>H<sub>11</sub>F<sub>2</sub>N<sub>3</sub>O, C, 66.87; H, 3.43; F, 11.75; N, 13.00; O, 4.95. Found: C, 66.90; H, 3.39; F, 11.83; N, 12.96; O, 4.92%. HRMS (m/z) [M&#x02009;+&#x02009;H]+ calcd 324.0943, found. 324.3554.</p><p><bold>6-(1-(2,3,4-Trifluorophenyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-ol 2L</bold> Yield 13%; mp (with decomposition) 212-214&#x02009;&#x000b0;C; &#x003bd;<sub>max</sub> (KBr)/cm<sup>&#x02212;1</sup> 3175, 1630, 1509, 1305, 1043, 912; <sup>1</sup>H NMR &#x003b4;<sub>H</sub> (400&#x02009;MHz, DMSO-d<sub>6</sub>) 9.88 (1H, s, OH), 9.14 (1H, d, <italic>J</italic>&#x02009;=&#x02009;1.7&#x02009;Hz, CH), 8.40 (1H, s, Ar-H), 7.97 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.5, 1.6&#x02009;Hz, Ar-H), 7.89-7.77 (3H, m, Ar-H), 7.65 (1H, qd, <italic>J</italic>&#x02009;=&#x02009;8.5, 1.6&#x02009;Hz, Ar-H), 7.18-7.16 (1H, m, Ar-H), 7.14 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.7, 2.3&#x02009;Hz, Ar-H); <sup>13</sup>C NMR &#x003b4;<sub>C</sub> (101&#x02009;MHz, DMSO-d<sub>6</sub>) 156.3, 152.4-152.0 (m), 149.8-149.5 (m), 147.9, 145.8-145.4 (m), 143.2-142.9 (m), 141.6-141.2 (m), 139.2-138.7 (m), 135.0, 130.2, 128.1, 127.3, 124.5, 124.5, 124.4, 123.1 (dd, <sup>3</sup><italic>J</italic><sub>C-F</sub> = 8.3, <sup>4</sup><italic>J</italic><sub>C-F</sub> = 3.7&#x02009;Hz), 122.9 (d, <sup>4</sup><italic>J</italic><sub>C-F</sub> = 3.3&#x02009;Hz), 121.0 (dd, <sup>3</sup><italic>J</italic><sub>C-F</sub> = 8.5, <sup>4</sup><italic>J</italic><sub>C-F</sub> = 3.9&#x02009;Hz), 119.8, 113.8 (dd, <sup>2</sup><italic>J</italic><sub>C-F</sub> = 18.6, <sup>3</sup><italic>J</italic><sub>C-F</sub> = 3.8&#x02009;Hz), 109.; Anal. calcd for: C<sub>18</sub>H<sub>10</sub>F<sub>3</sub>N<sub>3</sub>O, C, 63.35; H, 2.95; F, 16.70; N, 12.31; O, 4.69. Found: C, 63.41; H, 2.89; F, 16.78; N, 12.39; O, 4.53%. HRMS (m/z) [M&#x02009;+&#x02009;H]<sup>+</sup> calcd 342.0849, found. 342.3574.</p></sec><sec id="S0002-S2001-S3003" disp-level="3"><title>General method for the synthesis of 6-(1-phenyl-1H-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate derivatives 3A-L</title><p>A solution of chlorosulphonyl isocyanate (212.0&#x02009;mg, 1.50&#x02009;mmol) in anhydrous DCM (0.5&#x02009;ml) was prepared. In the next step, a solution of formic acid (70.9&#x02009;mg, 1.54&#x02009;mmol) and <italic>N</italic>,<italic>N</italic>-DMA (1.4&#x02009;mg, 0.016&#x02009;mmol) was added, and the reaction mixture was stirred at 40&#x02009;&#x000b0;C for 3.5&#x02009;h. Then, a solution of the corresponding derivative <bold>2A-L</bold> (1.00&#x02009;mmol) in <italic>N</italic>,<italic>N</italic>-DMA (3.4&#x02009;ml) was added, and the obtained solution was stirred at room temperature overnight. Subsequently, reaction mixture was poured into water (50&#x02009;ml). The resulting precipitate was filtered and washed with water. The crude product was recrystallized from ACN to give the desired products <bold>3A-L</bold>.</p><p><bold>6-(1-Phenyl-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate 3A</bold> Yield 70%; mp (with decomposition) 210-211&#x02009;&#x000b0;C; &#x003bd;max (KBr)/cm<sup>&#x02212;1</sup> 3119, 2915, 2358, 1595, 1352, 1168, 759, 672; <sup>1</sup>H NMR &#x003b4;<sub>H</sub> (400&#x02009;MHz, DMSO-d<sub>6</sub>) 9.47 (1H, s, CH), 8.59 (1H, s, Ar-H), 8.16 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.6, 1.5&#x02009;Hz, Ar-H), 8.15-8.10 (4H, m, Ar-H, NH<sub>2</sub>), 8.00 (2H, d, <italic>J</italic>&#x02009;=&#x02009;7.6&#x02009;Hz, Ar-H), 7.88 (1H, d, <italic>J</italic>&#x02009;=&#x02009;2.2&#x02009;Hz, Ar-H), 7.67 (2H, t, <italic>J</italic>&#x02009;=&#x02009;7.9&#x02009;Hz, Ar-H), 7.54 (1H, t, <italic>J</italic>&#x02009;=&#x02009;7.4&#x02009;Hz, Ar-H), 7.51 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.9, 2.4&#x02009;Hz, Ar-H); <sup>13</sup>C NMR &#x003b4;<sub>C</sub> (101&#x02009;MHz, DMSO-d<sub>6</sub>) 148.5, 147.6, 137.1, 133.4, 131.9, 130.5, 130.4, 129.3, 129.1, 128.4, 125.0, 124.0, 122.9, 120.6, 120.5, 119.8; Anal. calcd for: C<sub>18</sub>H<sub>14</sub>N<sub>4</sub>O<sub>3</sub>S, C, 59.01; H, 3.85; N, 15.29; O, 13.10; S, 8.75. Found: C, 58.98; H, 3.88; N, 15.34; O, 13.12; S, 8.68%. HRMS (m/z) [M&#x02009;+&#x02009;H]<sup>+</sup> calcd 367.0860, found 367.3750.</p><p><bold>6-(1-(3-Fluorophenyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate 3B</bold> Yield 43%; mp (with decomposition) 210-212&#x02009;&#x000b0;C; &#x003bd;<sub>max</sub> (KBr)/cm<sup>&#x02212;1</sup> 3120, 2560, 1600, 1358, 1173, 782, 673; <sup>1</sup>H NMR &#x003b4;<sub>H</sub> (400&#x02009;MHz, DMSO-d<sub>6</sub>) 9.52 (1H, s, CH), 8.58 (1H, s, Ar-H), 8.18-8.06 (5H, m, Ar-H, NH<sub>2</sub>), 7.96-7.86 (3H, m, Ar-H), 7.72 (1H, q, <italic>J</italic>&#x02009;=&#x02009;7.4&#x02009;Hz, Ar-H), 7.50 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.9, 2.2&#x02009;Hz, Ar-H), 7.41 (1H, td, <italic>J</italic>&#x02009;=&#x02009;8.7, 2.3&#x02009;Hz, Ar-H); <sup>13</sup>C NMR &#x003b4;<sub>C</sub> (101&#x02009;MHz, DMSO-d<sub>6</sub>) 162.9 (d, <sup>1</sup><italic>J</italic><sub>C-F</sub> = 245.2&#x02009;Hz), 148.6, 147.7, 138.3, (d, <sup>3</sup><italic>J</italic><sub>C-F</sub> = 10.5&#x02009;Hz), 133.5, 132.4 (d, <sup>3</sup><italic>J</italic><sub>C-F</sub> = 9.1&#x02009;Hz), 131.9, 130.5, 129.2, 128.2, 125.0, 124.1, 122.9, 120.8, 119.8, 116.4 (d, <sup>4</sup><italic>J</italic><sub>C-F</sub> = 3.0&#x02009;Hz), 116.0 (d, <sup>2</sup><italic>J</italic><sub>C-F</sub> = 21.0&#x02009;Hz), 108.0 (d, <sup>2</sup><italic>J</italic><sub>C-F</sub> = 26.5&#x02009;Hz); Anal. calcd for: C<sub>18</sub>H<sub>13</sub>FN<sub>4</sub>O<sub>3</sub>S, C, 56.24; H, 3.41; F, 4.94; N, 14.58; O, 12.49; S, 8.34. Found: C, 56.30; H, 3.45; F, 4.90; N, 14.60; O, 12.41; S, 8,43%. HRMS (m/z) [M&#x02009;+&#x02009;H]<sup>+</sup> calcd 385.0766, found 385.3810.</p><p><bold>6-(1-(3-Chlorophenyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate 3C</bold> Yield 67%; mp (with decomposition) 214-216&#x02009;&#x000b0;C; &#x003bd;<sub>max</sub> (KBr)/cm<sup>&#x02212;1</sup> 3132, 2915, 2376, 1591, 1381, 1177, 784, 676; <sup>1</sup>H NMR &#x003b4;<sub>H</sub> (400&#x02009;MHz, DMSO-d<sub>6</sub>) 9.53 (1H, s, CH), 8.57 (1H, s, Ar-H), 8.16-8.07 (6H, m, Ar-H, NH<sub>2</sub>), 8.01 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;7.9, 1.2&#x02009;Hz, Ar-H), 7.88 (1H, d, <italic>J</italic>&#x02009;=&#x02009;2.1&#x02009;Hz, Ar-H), 7.69 (1H, t, <italic>J</italic>&#x02009;=&#x02009;8.1&#x02009;Hz, Ar-H), 7.61 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.0, 0.8&#x02009;Hz, Ar-H), 7.51 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.9, 2.3&#x02009;Hz, Ar-H); <sup>13</sup>C NMR &#x003b4;<sub>C</sub> (101&#x02009;MHz, DMSO-d<sub>6</sub>) 148.5, 147.7, 138.1, 134.7, 133.5, 132.2, 131.9, 130.5, 129.2, 129.0, 128.2, 124.9, 124.1, 122.9, 120.8, 120.3, 119.8, 119.0; Anal. calcd for: C<sub>18</sub>H<sub>13</sub>ClN<sub>4</sub>O<sub>3</sub>S, C, 53.94; H, 3.27; Cl, 8.84; N, 13.98; O, 11.97; S, 8.00. Found: C, 53.98; H, 3.29; Cl, 8.80; N, 13.94; O, 11.92; S, 8.07%. HRMS (m/z) [M&#x02009;+&#x02009;H]<sup>+</sup> calcd 401.0470, found 401.3646.</p><p><bold>6-(1-(3-Bromophenyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate 3D</bold> Yield 34%; mp (with decomposition) 219-221&#x02009;&#x000b0;C; &#x003bd;<sub>max</sub> (KBr)/cm<sup>&#x02212;1</sup> 3298, 3171, 2363, 1484, 1368, 1182, 800; <sup>1</sup>H NMR &#x003b4;<sub>H</sub> (400&#x02009;MHz, DMSO-d<sub>6</sub>) 9.55 (1H, s, CH), 8.58 (1H, s, Ar-H), 8.26 (1H, t, <italic>J</italic>&#x02009;=&#x02009;1.8&#x02009;Hz, Ar-H), 8.16-8.09 (5H, m, Ar-H, NH<sub>2</sub>), 8.06 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.1, 1.2&#x02009;Hz, Ar-H), 7.88 (1H, d, <italic>J</italic>&#x02009;=&#x02009;2.1&#x02009;Hz, Ar-H), 7.75 (1H, d, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz, Ar-H), 7.63 (1H, t, <italic>J</italic>&#x02009;=&#x02009;8.1&#x02009;Hz, Ar-H), 7.50 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.9, 2.3&#x02009;Hz, Ar-H); <sup>13</sup>C NMR &#x003b4;<sub>C</sub> (101&#x02009;MHz, DMSO-d<sub>6</sub>) 148.6, 147.7, 138.2, 133.5, 132.4, 132.0, 131.9, 130.5, 129.2, 128.2, 124.9, 124.1, 123.0, 122.99, 122.90, 120.9, 119.8, 119.4; Anal. calcd for: C<sub>18</sub>H<sub>13</sub>BrN<sub>4</sub>O<sub>3</sub>S, C, 48.55; H, 2.94; Br, 17.94; N, 12.58; O, 10.78; S, 7.20. Found: C, 48.59; H, 2.96; Br, 17.90; N, 12.55; O, 10.74; S, 7.26%. HRMS (m/z) [M&#x02009;+&#x02009;H]<sup>+</sup> calcd 444.9965, found 445.3408.</p><p><bold>6-(1-(4-Fluorophenyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate 3E</bold> Yield 36%; mp (with decomposition) 226-227&#x02009;&#x000b0;C; &#x003bd;<sub>max</sub> (KBr)/cm<sup>&#x02212;1</sup> 3314, 3159, 1515, 1357, 1180, 838; <sup>1</sup>H NMR &#x003b4;<sub>H</sub> (400&#x02009;MHz, DMSO-d<sub>6</sub>) 9.44 (1H, s, CH), 8.57 (1H, s, Ar-H), 8.17-8.09 (5H, m, Ar-H, NH<sub>2</sub>), 8.07-8.01 (2H, m, Ar-H), 7.88 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;2.0&#x02009;Hz, Ar-H), 7.58-7.46 (3H, m, Ar-H); <sup>13</sup>C NMR &#x003b4;<sub>C</sub> (101&#x02009;MHz, DMSO-d<sub>6</sub>) 162.2 (d, <sup>1</sup><italic>J</italic><sub>C-F</sub> = 245.9&#x02009;Hz), 148.5, 147.6, 133.7 (d, <sup>4</sup><italic>J</italic><sub>C-F</sub> = 2.8&#x02009;Hz), 133.4, 131.9, 130.5, 129.1, 128.4, 125.0, 124.0, 122.9 (d, <sup>3</sup><italic>J</italic><sub>C-F</sub> = 5.0&#x02009;Hz), 122.8, 120.9, 119.8, 117.3 (d, <sup>2</sup><italic>J</italic><sub>C-F</sub> = 23.3&#x02009;Hz); Anal. calcd for: C<sub>18</sub>H<sub>13</sub>FN<sub>4</sub>O<sub>3</sub>S, C, 56.24; H, 3.41; F, 4.94; N, 14.58; O, 12.49; S, 8.34. Found: C, 56.27; H, 3.37; F, 4.93; N, 14.62; O, 12.53; S, 8.28%. HRMS (m/z) [M&#x02009;+&#x02009;H]<sup>+</sup> calcd 385.0766, found 385.3823.</p><p><bold>6-(1-(4-Chlorophenyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate 3F</bold> Yield 40%; mp (with decomposition) 226-229&#x02009;&#x000b0;C; &#x003bd;<sub>max</sub> (KBr)/cm<sup>&#x02212;1</sup> 3372, 3269, 1502, 1352, 1173, 813; <sup>1</sup>H NMR &#x003b4;<sub>H</sub> (400&#x02009;MHz, DMSO-d<sub>6</sub>) 9.49 (1H, s, CH), 8.58 (1H, s, Ar-H), 8.15-8.09 (5H, m, Ar-H, NH<sub>2</sub>), 8.04 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8.9&#x02009;Hz, Ar-H), 7.88 (1H, d, <italic>J</italic>&#x02009;=&#x02009;2.2&#x02009;Hz, Ar-H), 7.75 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8.8&#x02009;Hz, Ar-H), 7.50 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.9, 2.4&#x02009;Hz, Ar-H); <sup>13</sup>C NMR &#x003b4;<sub>C</sub> (101&#x02009;MHz, DMSO-d<sub>6</sub>) 148.5, 147.7, 135.9, 133.52, 133.48, 131.9, 130.5, 130.4, 129.2, 128.3, 125.0, 124.1, 122.9, 122.2, 120.7, 119.7; Anal. calcd for: C<sub>18</sub>H<sub>13</sub>ClN<sub>4</sub>O<sub>3</sub>S, C, 53.94; H, 3.27; Cl, 8.84; N, 13.98; O, 11.97; S, 8.00. Found: C, 53.90; H, 3.31; Cl, 8.91; N, 14.01; O, 11.94; S, 7.93%. HRMS (m/z) [M&#x02009;+&#x02009;H]<sup>+</sup> calcd 401.0470, found 401.3596.</p><p><bold>6-(1-(4-Bromophenyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate 3G</bold> Yield 45%; mp (with decomposition) 234-235&#x02009;&#x000b0;C; &#x003bd;<sub>max</sub> (KBr)/cm<sup>&#x02212;1</sup> 3378, 3273, 3143, 1498, 1144, 710; <sup>1</sup>H NMR &#x003b4;<sub>H</sub> (400&#x02009;MHz, DMSO-d<sub>6</sub>) 9.50 (1H, s, CH), 8.58 (1H, s, Ar-H), 8.16-8.10 (5H, m, Ar-H, NH<sub>2</sub>), 7.97 (2H, d, <italic>J</italic>&#x02009;=&#x02009;8.9&#x02009;Hz, Ar-H), 7.89-7.86 (3H, m, Ar-H), 7.50 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.9, 2.3&#x02009;Hz, Ar-H); <sup>13</sup>C NMR &#x003b4;<sub>C</sub> (101&#x02009;MHz, DMSO-d<sub>6</sub>) 148.5, 147.7, 136.3, 133.5, 133.4, 131.9, 130.5, 129.2, 128.2, 125.0, 124.1, 122.9, 122.4, 121.9, 120.7, 119.7; Anal. calcd for: C<sub>18</sub>H<sub>13</sub>BrN<sub>4</sub>O<sub>3</sub>S, C, 48.55; H, 2.94; Br, 17.94; N, 12.58; O, 10.78; S, 7.20. Found: C, 48.59; H, 2.90; Br, 17.97; N, 12.61; O, 10.81; S, 7.12%. HRMS (m/z) [M&#x02009;+&#x02009;H]<sup>+</sup> calcd 445.3490, found 446.9945.</p><p><bold>6-(1-(2-Fluorophenyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate 3H</bold> Yield 34%; mp (with decomposition) 206-207&#x02009;&#x000b0;C; &#x003bd;<sub>max</sub> (KBr)/cm<sup>&#x02212;1</sup> 3398, 3277, 3148, 1502, 1111, 728; <sup>1</sup>H NMR &#x003b4;<sub>H</sub> (400&#x02009;MHz, DMSO-d<sub>6</sub>) 9.50 (1H, d, <italic>J</italic>&#x02009;=&#x02009;1.8&#x02009;Hz, CH), 8.61 (1H, s, Ar-H), 8.21-8.06 (5H, m, Ar-H, NH<sub>2</sub>), 7.95 (1H, td, <italic>J</italic>&#x02009;=&#x02009;7.9, 1.1&#x02009;Hz, Ar-H), 7.88 (1H, d, <italic>J</italic>&#x02009;=&#x02009;2.0&#x02009;Hz, Ar-H), 7.70-7.60 (2H, m, Ar-H), 7.55-7.45 (2H, m, Ar-H); <sup>13</sup>C NMR &#x003b4;<sub>C</sub> (101&#x02009;MHz, DMSO-d<sub>6</sub>) 154.5 (d, <sup>1</sup><italic>J</italic><sub>C-F</sub> = 250.9&#x02009;Hz), 148.5, 147.2, 133.5, 131.9, 130.5, 129.1, 128.2, 126.5, 126.1 (d, <sup>3</sup><italic>J</italic><sub>C-F</sub> = 3.8&#x02009;Hz), 125.3 (d, <sup>2</sup><italic>J</italic><sub>C-F</sub> = 10.5&#x02009;Hz), 125.1, 124.1, 123.8 (d, <sup>3</sup><italic>J</italic><sub>C-F</sub> = 4.1&#x02009;Hz), 122.9, 119.7, 117.8, 117.6; Anal. calcd for: C<sub>18</sub>H<sub>13</sub>FN<sub>4</sub>O<sub>3</sub>S, C, 56.24; H, 3.41; F, 4.94; N, 14.58; O, 12.49; S, 8.34. Found: C, 56.31; H, 3.39; F, 4.90; N,14.56; O, 12.53; S, 8.31%. HRMS (m/z) [M&#x02009;+&#x02009;H]<sup>+</sup> calcd 385.0766, found 385.3785.</p><p><bold>6-(1-(2-Bromophenyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate 3J</bold> Yield 52%; mp (with decomposition) 188-189&#x02009;&#x000b0;C; &#x003bd;<sub>max</sub> (KBr)/cm<sup>&#x02212;1</sup> 3307, 3146, 3052, 1605, 1491, 1370, 929; <sup>1</sup>H NMR &#x003b4;<sub>H</sub> (400&#x02009;MHz, DMSO-d<sub>6</sub>) 9.19 (1H, s, CH), 8.60 (1H, s, Ar-H), 8.20-8.06 (5H, m, Ar-H, NH<sub>2</sub>), 7.98 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.0, 1.3&#x02009;Hz, Ar-H), 7.88 (1H, d, <italic>J</italic>&#x02009;=&#x02009;2.2&#x02009;Hz, Ar-H), 7.79 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;7.8, 1.6&#x02009;Hz, Ar-H), 7.68 (1H, td, <italic>J</italic>&#x02009;=&#x02009;7.6, 1.4&#x02009;Hz, Ar-H), 7.61 (1H, td, <italic>J</italic>&#x02009;=&#x02009;7.7, 1.7&#x02009;Hz, Ar-H), 7.50 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.9, 2.4&#x02009;Hz, Ar-H); <sup>13</sup>C NMR &#x003b4;<sub>C</sub> (101&#x02009;MHz, DMSO-d<sub>6</sub>) 153.7, 150.4, 137.9, 133.1, 132.2, 132.1, 131.4, 129.0, 128.9, 128.5, 126.2, 125.8, 124.7, 122.1, 120.7, 118.7, 115.5, 114.9; Anal. calcd for: C<sub>18</sub>H<sub>13</sub>BrN<sub>4</sub>O<sub>3</sub>S, C, 48.55; H, 2.94; Br, 17.94; N, 12.58; O, 10.78; S, 7.20. Found: C, 48.59, H, 2.96; Br, 17.93; N, 12.57; O, 10.72; S, 7.23%. HRMS (m/z) [M&#x02009;+&#x02009;H]<sup>+</sup> calcd 444.9965, found. 445.3399</p><p><bold>6-(1-(3,5-Difluorophenyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate 3K</bold> Yield 37%; mp (with decomposition) 214-215&#x02009;&#x000b0;C; &#x003bd;<sub>max</sub> (KBr)/cm<sup>&#x02212;1</sup> 3296, 3153, 3052, 1627, 1473, 1357, 916; <sup>1</sup>H NMR &#x003b4;<sub>H</sub> (400&#x02009;MHz, DMSO-d<sub>6</sub>) 9.55 (1H, s, CH), 8.56 (1H, s, Ar-H), 8.19-8.05 (5H, m, Ar-H, NH<sub>2</sub>), 7.88 (1H, d, <italic>J</italic>&#x02009;=&#x02009;2.1&#x02009;Hz, Ar-H), 7.85 (2H, dd, <italic>J</italic>&#x02009;=&#x02009;7.8, 2.0&#x02009;Hz, Ar-H), 7.51 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.8, 2.3&#x02009;Hz, Ar-H), 7.46 (1H, dt, <italic>J</italic>&#x02009;=&#x02009;9.2, 2.2&#x02009;Hz, Ar-H); <sup>13</sup>C NMR &#x003b4;<sub>C</sub> (101&#x02009;MHz, DMSO-d<sub>6</sub>) 163.3 (dd, <sup>1</sup><italic>J</italic><sub>C-F</sub> = 247.0&#x02009;Hz, <sup>3</sup><italic>J</italic><sub>C-F</sub> = 14.6&#x02009;Hz), 148.6, 147.7, 138.8 (t, <sup>3</sup><italic>J</italic><sub>C-F</sub> = 13.2&#x02009;Hz), 133.6, 131.9, 130.5, 129.3, 128.0, 124.9, 124.2, 122.9, 121.0, 119.8, 104.8, 104.5, 104.; Anal. calcd for: C<sub>18</sub>H<sub>12</sub>F<sub>2</sub>N<sub>4</sub>O<sub>3</sub>S, C, 53.73; H, 3.01; F, 9.44; N, 13.92; O, 11.93; S, 7.97. Found: C, 53.76; H, 3.06; F, 9.39; N, 13.87; O, 11.96; S, 7.96%. HRMS (m/z) [M&#x02009;+&#x02009;H]+ calcd 403.0671, found. 403.3818.</p><p><bold>6-(1-(2,3,4-Trifluorophenyl)-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate 3L</bold> Yield 26%; mp (with decomposition) 198-200&#x02009;&#x000b0;C; &#x003bd;<sub>max</sub> (KBr)/cm<sup>&#x02212;1</sup> 3262, 3175, 3021, 1618, 1509, 1384, 915; <sup>1</sup>H NMR &#x003b4;<sub>H</sub> (400&#x02009;MHz, DMSO-d<sub>6</sub>) 9.27 (1H, d, <italic>J</italic>&#x02009;=&#x02009;1.6&#x02009;Hz, CH), 8.61 (1H, s, Ar-H), 8.20-8.07 (5H, m, Ar-H, NH<sub>2</sub>), 7.91-7.83 (2H, m, Ar-H), 7.67 (1H, qd, <italic>J</italic>&#x02009;=&#x02009;9.8, 2.2&#x02009;Hz, Ar-H), 7.50 (1H, dd, <italic>J</italic>&#x02009;=&#x02009;8.9, 2.3&#x02009;Hz, Ar-H); <sup>13</sup>C NMR &#x003b4;<sub>C</sub> (101&#x02009;MHz, DMSO-d<sub>6</sub>) 152.4&#x02013;152.1 (m), 149.9-149.6 (m), 148.6, 147.3, 145.9-145.6 (m), 143.3-143.0 (m), 141.7-141.2 (m), 139.2&#x02013;138.7 (m), 133.5, 131.9, 130.5, 129.2, 127.9, 125.0, 124.3, 123.8 (d, <sup>4</sup><italic>J</italic><sub>C-F</sub> = 3.3&#x02009;Hz), 123.0 (dd, <sup>3</sup><italic>J</italic><sub>C-F</sub> = 8.3, <sup>4</sup><italic>J</italic><sub>C-F</sub> = 3.7&#x02009;Hz), 122.9, 121.1 (dd, <sup>3</sup><italic>J</italic><sub>C-F</sub> = 8.5, <sup>4</sup><italic>J</italic><sub>C-F</sub> = 4.0&#x02009;Hz), 119.7, 113.8 (dd, <sup>2</sup><italic>J</italic><sub>C-F</sub> = 18.6, <sup>3</sup><italic>J</italic><sub>C-F</sub> = 3.8&#x02009;Hz); Anal. calcd for: C<sub>18</sub>H<sub>11</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub>S, C, 51.43; H, 2.64; F, 13.56; N, 13.33; O, 11.42; S, 7.63. Found: C, 51.39; H, 2.71; F, 13.51; N, 13.29; O, 11.48; S, 7.62%. HRMS (m/z) [M&#x02009;+&#x02009;H]<sup>+</sup> calcd 421.0577, found. 421.3945.</p></sec></sec><sec id="S0002-S2002" disp-level="2"><title>Molecular docking</title><sec id="S0002-S2002-S3001" disp-level="3"><title>Ligands and molecular target preparation</title><p>The 3&#x02009;D structures of the potential steroid sulphatase inhibitors (ligands) were prepared using Portable HyperChem 8.0.7 Release (Hypercube, Inc., Gainesville, FL, USA)<xref rid="CIT0029" ref-type="bibr"><sup>29</sup></xref>. Before docking calculations, the structures of all ligands were optimised with an MM&#x02009;+&#x02009;force field<xref rid="CIT0030" ref-type="bibr"><sup>30</sup></xref> and the Polak-Ribi&#x000e8;re conjugate gradient algorithm (terminating at a gradient of 0.05&#x02009;kcal&#x000b7;mol<sup>&#x02212;1&#x02009;</sup>&#x000c5;<sup>&#x02212;1</sup>). The X-ray structure of human STS was obtained from Protein Data Bank (accession code 1P49) and was prepared using standard procedure. Initially, the NAG, BOG, PO<sub>4</sub><sup>3&#x02013;</sup> and water molecules from crystallisation were removed from the structure, and the catalytic amino acid fGly75 was converted to <italic>gem</italic>-diol form using the Maestro Protein Preparation Wizard module (Schr&#x000f6;dinger, LLC, New York, NY, USA)<xref rid="CIT0031" ref-type="bibr"><sup>31</sup></xref>. Then, hydrogen atoms were introduced into the structure, and prepared model of the enzyme was optimised using the OPLS-AA force field<xref rid="CIT0032" ref-type="bibr"><sup>32</sup></xref>.</p></sec><sec id="S0002-S2002-S3002" disp-level="3"><title>Molecular docking</title><p>Docking calculations of the optimised ligands to the prepared structure of human STS were carried out with AutoDock Vina 1.1.2 software (The Molecular Graphic Laboratory, The Scripps Research Institute, La Jolla, CA, USA)<xref rid="CIT0033" ref-type="bibr"><sup>33</sup></xref>. For all of docking studies, a grid box was centred on the C&#x003b2; atom of amino acid 75 of the prepared STS structure, and the size of the grid box was 24&#x02009;&#x000c5; &#x000d7; 24&#x02009;&#x000c5; &#x000d7; 24&#x02009;&#x000c5;. Then, the best binding modes for a particular ligand were inspected visually. Illustrations of the 3D models were prepared using VMD 1.9 (University of Illinois at Urbana-Champaign, Urbana, IL, USA)<xref rid="CIT0034" ref-type="bibr"><sup>34</sup></xref>. Identification of the ligand-protein interactions was performed using Discovery Studio Visualiser v20. 1. 0. 19295 (BIOVIA, Dassault Syst&#x000e9;mes, San Diego, CA, USA)<xref rid="CIT0035" ref-type="bibr"><sup>35</sup></xref>.</p></sec></sec><sec id="S0002-S2003" disp-level="2"><title>Biological assays</title><sec id="S0002-S2003-S3001" disp-level="3"><title><italic>In vitro</italic> STS assay</title><p>The STS enzyme was extracted from the human placenta, and purified using the 3-step chromatographic procedure according to the described method<xref rid="CIT0036" ref-type="bibr"><sup>36</sup></xref>. The reaction mixtures, at a final volume of 100&#x02009;&#x000b5;L, containing 20&#x02009;mM Tris-HCl pH = 7.4, 3&#x02009;nM radiolabelled [<sup>3</sup>H] oestrone sulphate, various concentrations of inhibitor and 5&#x02009;U of purified enzyme (1&#x02009;U is the amount of enzyme that hydrolyses 100&#x02009;nM radiolabelled [<sup>3</sup>H] oestrone sulphate in 1&#x02009;h at 37&#x02009;&#x000b0;C). The reactions were performed at 37&#x02009;&#x000b0;C for 30&#x02009;min. Afterwards, the reaction mixtures (90&#x02009;&#x000b5;L) were collected from each well, and the product formed by STS-mediated hydrolysis of [<sup>3</sup>H]E1 was extracted with toluene (0.5&#x02009;ml). Next 0.3&#x02009;ml of toluene was combined with 0.3&#x02009;ml of scintillation liquid. STS activity was measured using the radioluminometer MicroBeta (Perkin Elmer). Assays were performed in triplicate.</p></sec><sec id="S0002-S2003-S3002" disp-level="3"><title><italic>In vitro</italic> cellular assay using MCF-7 breast cancer cell line</title><p>Inhibition of STS activity in the MCF-7 breast cancer cell line was measured according to the method described by Purohit et&#x000a0;al. <xref rid="CIT0037" ref-type="bibr"><sup>37</sup></xref>. MCF-7 cells were maintained in Dulbecco&#x02019;s Modified Eagle Medium supplemented with 10% of foetal bovine serum and cultured until 80% of confluence was received. Cells were seeded in 24-well microplates (Nest Biotechnology) at a density of 1&#x000b7;10<sup>5</sup> cells/well. In order to assure an equal amount of cells in each reaction sample the number of cells was determined using a B&#x000fc;rker Counting Chamber. The STS activity was evaluated in living MCF-7 cells. Incubation of cells was conducted for 20&#x02009;h at 37&#x02009;&#x000b0;C in a 5% CO<sub>2</sub> humidified incubator in a serum-free medium (0.5&#x02009;ml) with radiolabelled oestrone sulphate [<sup>3</sup>H]E1S (4&#x000b7;105&#x02009;cpm, 3&#x02009;nM) with or without an inhibitor. After incubation, a medium containing STS-mediated reaction product was collected (0.45&#x02009;ml) from each well and the product was isolated from the mixture by extraction with toluene (4&#x02009;ml). The STS activity expressed as the level of product radioactivity was measured using the Radioluminometer MicroBeta (Perkin Elmer). Cellular assay was carried out in triplicate. IC<sub>50</sub> values were calculated using GraphPad Prism software.</p></sec></sec></sec><sec sec-type="results" id="S0003" disp-level="1"><title>Results and discussion</title><sec id="S0003-S2001" disp-level="2"><title>Molecular docking</title><p>Initially, to verify that the 6&#x02013;(1-phenyl-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate derivatives are able to effectively bind to the STS active site, molecular docking studies were performed. The X-ray structure of STS was retrieved from the Protein Data Bank (Protein Data Bank accession code 1P49) and properly prepared for docking calculations. The docking procedure of the optimised ligands was performed using AutoDock Vina 1.1.2 software (Molecular Graphics Laboratory, The Scripps Research Institute, LaJolla, CA). The calculated results for the proposed structures of the inhibitors <bold>3A-L</bold> were at a satisfactory, comparable level in the range of &#x02212;6.0 to &#x02212;8.3&#x02009;kcal&#x000b7;mol<sup>&#x02212;1</sup> (the measurement error for the AutoDock Vina software is 2.85&#x02009;kcal&#x000b7;mol<sup>&#x02212;1</sup>) (<xref rid="t0001" ref-type="table">Table 1</xref>) and lower than the free energy of binding value of the reference inhibitor <italic>Irosustat</italic> (&#x02013;5.4&#x02009;kcal&#x000b7;mol<sup>&#x02212;1</sup>). The most favourable binding energy was determined for compound <bold>3L</bold> (&#x02013;8.3&#x02009;kcal&#x000b7;mol<sup>&#x02212;1</sup>) suggesting that this compound could theoretically create the most stable inhibitor-enzyme complex in the STS active site, leading to effective inhibition.</p><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Free energies of binding calculated for compounds <bold>3&#x02009;A-L</bold> and <italic>Irosustat</italic>.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th colspan="7" align="left"><inline-graphic xlink:href="IENZ_A_1858820_ILG0001_B.gif" content-type="black-white"/><hr/></th></tr><tr><th align="left">No.</th><th align="center">R<sub>1</sub></th><th align="center">R<sub>2</sub></th><th align="center">R<sub>3</sub></th><th align="center">R<sub>4</sub></th><th align="center">R<sub>5</sub></th><th align="center">Free energies of binding [kcal&#x000b7;mol<sup>-1</sup>]</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>3A</bold></td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="center">&#x02013;7.4</td></tr><tr><td align="left"><bold>3B</bold></td><td align="center">H</td><td align="center">F</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="center">&#x02013;7.7</td></tr><tr><td align="left"><bold>3C</bold></td><td align="center">H</td><td align="center">Cl</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="center">&#x02013;6.4</td></tr><tr><td align="left"><bold>3D</bold></td><td align="center">H</td><td align="center">Br</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="center">&#x02013;6.3</td></tr><tr><td align="left"><bold>3E</bold></td><td align="center">H</td><td align="center">H</td><td align="center">F</td><td align="center">H</td><td align="center">H</td><td align="center">&#x02013;7.6</td></tr><tr><td align="left"><bold>3F</bold></td><td align="center">H</td><td align="center">H</td><td align="center">Cl</td><td align="center">H</td><td align="center">H</td><td align="center">&#x02013;7.6</td></tr><tr><td align="left"><bold>3G</bold></td><td align="center">H</td><td align="center">H</td><td align="center">Br</td><td align="center">H</td><td align="center">H</td><td align="center">&#x02013;6.0</td></tr><tr><td align="left"><bold>3H</bold></td><td align="center">F</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="center">&#x02013;8.0</td></tr><tr><td align="left"><bold>3I</bold></td><td align="center">Cl</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="center">&#x02013;7.9</td></tr><tr><td align="left"><bold>3J</bold></td><td align="center">Br</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="center">&#x02013;8.0</td></tr><tr><td align="left"><bold>3K</bold></td><td align="center">H</td><td align="center">F</td><td align="center">H</td><td align="center">F</td><td align="center">H</td><td align="center">&#x02013;7.9</td></tr><tr><td align="left"><bold>3L</bold></td><td align="center">F</td><td align="center">F</td><td align="center">F</td><td align="center">H</td><td align="center">H</td><td align="center">&#x02013;8.3</td></tr><tr><td align="left"><italic toggle="yes">Irosustat</italic></td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="center">&#x02013;5.4</td></tr></tbody></table></table-wrap><p>In order to analyse the ligand-protein interactions that could be responsible for the stabilisation of the inhibitor-enzyme complexes, studies using BIOVIA, Dassault Syst&#x000e9;mes, Discovery Studio Visualiser software have been carried out. Our research has shown that the newly designed potential STS inhibitors based on 6&#x02013;(1-phenyl-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate derivatives were able to create the complexes with the STS protein stabilised by a number of interactions including &#x003c0;-alkyl, alkyl, &#x003c0;-sulphur, conventional hydrogen bond, carbon hydrogen bond, &#x003c0;-cation, or &#x003c0;-sigma (listed in <xref rid="t0002" ref-type="table">Table 2</xref>). The largest number of interactions was detected for compounds <bold>3E</bold>, <bold>3F</bold>, <bold>3G</bold>. However, apart from the above-mentioned numerous interactions, an extremely important aspect (influencing the inhibitory properties of STS inhibitors based on aryl-sulphamate derivatives) is their ability to undergo the nucleophilic substitution reactions on the sulphur atom. Although the mechanism of action is not confirmed and remains a topic of discussion, a sulphamate functional group (sulphate mimic) might be transferred to fGly75 residue leading to irreversible inhibition of the STS enzyme<xref rid="CIT0021" ref-type="bibr"><sup>21</sup></xref>. The visualisation of the putative binding mode for compounds <bold>3L</bold> using VMD 1.9 (University of Illinois at Urbana-Champaign, Urbana, IL, USA) is shown in <xref ref-type="fig" rid="F0001">Figure 1</xref>. The sulphamate functional group, which is directly responsible for the inactivation of the enzyme, is located in the catalytic region of STS close to the fGly75 residue coordinated to Ca<sup>2+</sup> and stabilised by &#x003c0;-sulphur interaction with His290 (the distance between the sulphur atom of <bold>3L</bold> and OH group of fGly75 is 2.90&#x02009;&#x000c5;). For this reason, we suppose that the compound <bold>3L</bold> (despite a smaller number of electrostatic interactions indicated by the docking program) may prove to be the most effective due to the very close distance of the sulphamate group to fGly75 residue. Furthermore, the tetracyclic core of compound <bold>3L</bold> is well accommodated in the STS active site and is surrounded by some hydrophobic amino acid residues (e.g. Leu103, Leu167, Phe178, Phe182, Phe237, Val486, Phe488, and Phe553). Interestingly, the fluorine atoms of compound <bold>3L</bold> are within a short distance to the nitrogen atoms of the Arg98 residue (4.12 and 4.29&#x02009;&#x000c5;), indicating the possibility of electrostatic interactions (undetected by the Discovery Studio Visualiser). On the other hand, the presence of the fluorine atoms may be crucial for its potentially increased ability to undergo the enzymatic reaction. Highly electronegative fluorine atoms may reduce the pKa value of the molecule, making it a good leaving group in the nucleophilic substitution reaction on the sulphur atom. In addition, the molecular modelling studies indicated (<xref ref-type="fig" rid="F0001">Figure 1</xref>) that the triazole ring of compound <bold>3L</bold> is located close to the Thr484 residue, suggesting an additional interaction including hydrogen bond between OH group of Thr484 and ring-nitrogen atom (5.81&#x02009;&#x000c5;). These detected interaction points may be responsible for an enhancement of inhibitory potency by stabilisation of the potential STS inhibitor in the enzyme&#x02019;s active site.</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Docked binding modes and distance to fGly75, Arg98 and Thr484 for compound <bold>3&#x02009;L</bold> (CPK coloured) and <italic>Irosustat</italic> (pink).</p></caption><graphic content-type="color" xlink:href="IENZ_A_1858820_F0001_C"/></fig><table-wrap id="t0002" orientation="portrait" position="float"><label>Table 2.</label><caption><p>The ligand-protein interactions (and distances [&#x000c5;]) identified using BIOVIA, Dassault Syst&#x000e9;mes, Discovery Studio Visualiser.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th colspan="8" align="left"><inline-graphic xlink:href="IENZ_A_1858820_ILG0002_C.gif" content-type="color"/><hr/></th></tr><tr><th align="left">No.</th><th align="center">&#x003c0;&#x02013;Alkyl</th><th align="center">Alkyl</th><th align="center">&#x003c0;&#x02013;Sulphur</th><th align="center">Conventional Hydrogen Bond</th><th align="center">Carbon Hydrogen Bond</th><th align="center">&#x003c0;&#x02013;Cation</th><th align="center">&#x003c0;&#x02013;Sigma</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>3A</bold></td><td align="left">LEU103 (6.16, 6.50); VAL486 (5.86); VAL101 (4.93, 6.33); VAL177 (6.12)</td><td align="center">&#x02013;</td><td align="left">HIS290 (5.76); HIS136 (6.93)</td><td align="left">THR165 (4.11)</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td></tr><tr><td align="left"><bold>3B</bold></td><td align="left">LEU103 (6.13, 6.47); VAL486 (5.50, 6.07), VAL101 (5.31), VAL177 (5.50, 5.57)</td><td align="center">&#x02013;</td><td align="left">HIS290 (6.00)</td><td align="left">FGLY75 (4.18), LYS368 (5.02)</td><td align="left">HIS136 (5.74, 7.12)</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td></tr><tr><td align="left"><bold>3C</bold></td><td align="left">LEU103 (5.91); VAL486 (6.16); VAL101 (5.43); VAL177 (5.43, 5.63)</td><td align="left">ARG98 (2.99), TRP550 (6.97)</td><td align="left">HIS290 (5.75);<break/>HIS136 (7.13)</td><td align="center">&#x02013;</td><td align="left">HIS136 (6.04)</td><td align="left">ARG98 (4.40)</td><td align="center">&#x02013;</td></tr><tr><td align="left"><bold>3D</bold></td><td align="left">LEU103 (5.51); VAL101 (4.85); VAL177 (4.85, 5.55)</td><td align="left">ARG98 (3.08); TRP550 (6.86)</td><td align="left">HIS290 (5.79);<break/>HIS136 (7.11)</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="left">ARG98 (4.83)</td><td align="left">&#x000a0;</td></tr><tr><td align="left"><bold>3E</bold></td><td align="left">ARG98 (4.57, 6.35);<break/>VAL177 (6.26); VAL486 (5.36), VAL101 (6.07)</td><td align="center">&#x02013;</td><td align="left">HIS290 (5.43); HIS136 (6.78)</td><td align="left">LYS134 (6.65); ASP36 (4.96); GLN343 (5.61)</td><td align="left">THR165 (5.41)</td><td align="center">&#x02013;</td><td align="left">VAL101 (4.93)</td></tr><tr><td align="left"><bold>3F</bold></td><td align="left">ARG98 (4.74); VAL177<break/>(6.49); VAL101 (5.81), VAL486 (5.37)</td><td align="center">&#x02013;</td><td align="left">HIS290 (5.29); HIS136 (6.73)</td><td align="left">LYS134 (5.37), THR165 (4.20)</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="left">VAL101 (4.78)</td></tr><tr><td align="left"><bold>3G</bold></td><td align="left">ARG98 (4.95); VAL177 (5.24, 5.96), VAL486 (5.30), VAL101 (6.42)</td><td align="left">LEU185 (5.88)</td><td align="left">HIS290 (4.87,<break/>5.32); HIS136<break/>(6.72)</td><td align="left">LYS368 (5.58), LYS134 (6.45), GLN343 (5.45), ASP36 (4.95), ASP35 (4.95)</td><td align="left">HIS136 (5.58)</td><td align="center">&#x02013;</td><td align="left">VAL101 (5.29)</td></tr><tr><td align="left"><bold>3H</bold></td><td align="left">LEU103 (6.23, 6.49); VAL486 (6.21); VAL101 (5.38); VAL177 (5.49, 5.69)</td><td align="center">&#x02013;</td><td align="left">HIS290 (5.96); HIS136 (7.09)</td><td align="left">FGLY75 (4.25, 5.14); LYS368<break/>(3.69)</td><td align="left">HIS136 (5.74)</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td></tr><tr><td align="left"><bold>3I</bold></td><td align="left">PHE178 (4.53); LEU103 (6.27, 6.56); VAL177 (5.46, 5.79); VAL486 (5.96), VAL101 (5.42)</td><td align="center">&#x02013;</td><td align="left">HIS290 (6.01); HIS136 (7.08)</td><td align="left">LYS368 (5.15)</td><td align="left">HIS136 (5.73)</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td></tr><tr><td align="left"><bold>3J</bold></td><td align="left">PHE178 (4.48); LEU103<break/>(6.15, 6.43), VAL177 (5.50, 5.67); VAL486 (6.08); <break/>VAL101 (5.34)</td><td align="center">&#x02013;</td><td align="left">HIS290 (5.92); <break/>HIS136 (7.05)</td><td align="left">LYS368 (5.18); FGLY75 (3.04, <break/>4.27)</td><td align="left">HIS136 (5.69)</td><td align="left">ARG98 (4.90)</td><td align="center">&#x02013;</td></tr><tr><td align="left"><bold>3K</bold></td><td align="left">LEU103 (6.18, 6.60); <break/>VAL486 (5.95); VAL101<break/>(5.40); VAL177 (5.26, 5.68)</td><td align="center">&#x02013;</td><td align="left">HIS290 (5.91); <break/>HIS136 (7.05)</td><td align="left">ARG98 (5.14)</td><td align="left">HIS136 (5.67)</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td></tr><tr><td align="left"><bold>3L</bold></td><td align="left">VAL177 (4.32); VAL486 (5.09, 5.61); LEU74 (6.53)</td><td align="center">&#x02013;</td><td align="left">HIS290 (5.57)</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="left">VAL101 (5.12)</td></tr><tr><td align="left"><italic toggle="yes">Irosustat</italic></td><td align="left">VAL177 (6.51); VAL486<break/>(4.87, 5.08) VAL101 (5.09)</td><td align="center">&#x02013;</td><td align="left">HIS290 (5.73); <break/>HIS136 (6.84)</td><td align="left">LYS368 (5.49); <break/>FGLY75 (3.04)</td><td align="left">HIS136 (6.03)</td><td align="center">&#x02013;</td><td align="left">VAL486 (4.67)</td></tr></tbody></table></table-wrap></sec><sec id="S0003-S2002" disp-level="2"><title>Chemistry</title><p>The newly designed compounds <bold>3A-L</bold> based on 6&#x02013;(1-phenyl-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate derivatives were synthesised according to the route shown in (<xref ref-type="scheme" rid="SCH001">Scheme 1</xref>). In the first step, we synthesised 6-((trimethylsilyl)ethynyl)naphthalen-2-ol <bold>1</bold> by the Sonogashira coupling reaction between 6-bromo-2-naphthol and trimethylsilylacetylene. Next step included the preparation of 6&#x02013;(1-phenyl-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-ol derivatives <bold>2&#x02009;A-L</bold> by a 1,3-dipolar cycloaddition reaction. In this case the corresponding azide derivatives (obtained from commercially available anilines by the reaction with <italic>t</italic>-BuONO and TMSN<sub>3</sub>) were treated with <bold>1</bold> in the presence of CuSO<sub>4</sub> &#x000b7; 5H<sub>2</sub>O (0.1 equiv.), sodium ascorbate (0.2 equiv.), and TBAF. Finally, 6&#x02013;(1-phenyl-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-ol derivatives <bold>2&#x02009;A-L</bold> were sulphamoylated using sulphamoyl chloride previously generated in the reaction of chlorosulphonyl isocyanate and formic acid in the presence of a catalytic amount of <italic>N</italic>,<italic>N</italic>-DMA. After standard isolation, the desired derivatives <bold>3A-L</bold> were obtained.</p><fig id="SCH001" orientation="portrait" position="float"><label>Scheme 1.</label><caption><p>Synthesis of 6-((trimethylsilyl)ethynyl)naphthalen-2-ol <bold>1</bold> and 6&#x02013;(1-phenyl-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate derivatives (R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub> = H, F, Cl, or Br) <bold>3&#x02009;A-L</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1858820_SCH0001_B"/></fig></sec><sec id="S0003-S2003" disp-level="2"><title>Biological evaluation</title><sec id="S0003-S2003-S3001" disp-level="3"><title>Enzymatic assay using the STS enzyme isolated from the human placenta</title><p>In the next step of our investigation, the synthesised new STS inhibitors based on 6&#x02013;(1-phenyl-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate derivatives <bold>3A-L</bold> were tested in the enzymatic assay (at 0.5&#x02009;&#x000b5;M of inhibitor concentration) in order to verify their theoretical potential to inhibit of the STS activity. Screening tests were performed using the STS enzyme isolated from the human placenta and purified by a 3-step chromatography procedure. After purification, the obtained fraction was used directly as the enzyme source. In this activity assay, a radiolabelled [<sup>3</sup>H] oestrone sulphate has been used as a substrate to provide higher selectivity and more reliable results. The summarised results of the enzymatic assay for newly synthesised 6&#x02013;(1-phenyl-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate derivatives <bold>3A-L</bold> are presented in <xref rid="t0003" ref-type="table">Table 3</xref>. The received data showed that all compounds effectively inhibited the activity of the steroid sulphatase to a level from 7.98 to 27.17%. In the course of the research, we found that the highest inhibitory activity was exhibited by the compound <bold>3L</bold> containing three fluorine atoms in its structure (remaining STS activity of 7.98%). This result was in agreement with the data from the molecular modelling studies. It was observed that the substitution of the terminal aromatic ring with a less halogen atoms resulted in a decrease in the activity of the tested compounds towards STS. This observation may confirm our assumptions that the higher number of electronegative heteroatoms may reduce the pKa value of the inhibitor cores, making them more susceptible to nucleophilic substitution reaction on the sulphur atom. The obtained results may also suggest that the position of the halogen substitution in the above-mentioned aryl ring may be crucial for the potency of evaluated compounds. As it turns out, the presence of halogen atoms at the R<sub>1</sub> and R<sub>2</sub> positions may have the greatest influence on the increase of inhibitory potency. On the other hand, the type of substituent is slightly less significant.</p><table-wrap id="t0003" orientation="portrait" position="float"><label>Table 3.</label><caption><p>The STS inhibitory effect of the newly synthesised compounds <bold>3&#x02009;A-L</bold> at 0.5&#x02009;<italic>&#x000b5;</italic>M inhibitor concentration.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th colspan="7" align="left"><inline-graphic xlink:href="IENZ_A_1858820_ILG0003_B.gif" content-type="black-white"/><hr/></th></tr><tr><th align="left">No.</th><th align="center">R<sub>1</sub></th><th align="center">R<sub>2</sub></th><th align="center">R<sub>3</sub></th><th align="center">R<sub>4</sub></th><th align="center">R<sub>5</sub></th><th align="center">Remaining STS activity [%]</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>3A</bold></td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="char" char="&#x000b1;">24.50&#x02009;&#x000b1;&#x02009;1.36</td></tr><tr><td align="left"><bold>3B</bold></td><td align="center">H</td><td align="center">F</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="char" char="&#x000b1;">17.40&#x02009;&#x000b1;&#x02009;0.87</td></tr><tr><td align="left"><bold>3C</bold></td><td align="center">H</td><td align="center">Cl</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="char" char="&#x000b1;">9.66&#x02009;&#x000b1;&#x02009;0.48</td></tr><tr><td align="left"><bold>3D</bold></td><td align="center">H</td><td align="center">Br</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="char" char="&#x000b1;">9.62&#x02009;&#x000b1;&#x02009;0.48</td></tr><tr><td align="left"><bold>3E</bold></td><td align="center">H</td><td align="center">H</td><td align="center">F</td><td align="center">H</td><td align="center">H</td><td align="char" char="&#x000b1;">23.75&#x02009;&#x000b1;&#x02009;1.22</td></tr><tr><td align="left"><bold>3F</bold></td><td align="center">H</td><td align="center">H</td><td align="center">Cl</td><td align="center">H</td><td align="center">H</td><td align="char" char="&#x000b1;">18.71&#x02009;&#x000b1;&#x02009;0.94</td></tr><tr><td align="left"><bold>3G</bold></td><td align="center">H</td><td align="center">H</td><td align="center">Br</td><td align="center">H</td><td align="center">H</td><td align="char" char="&#x000b1;">23.07&#x02009;&#x000b1;&#x02009;1.15</td></tr><tr><td align="left"><bold>3H</bold></td><td align="center">F</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="char" char="&#x000b1;">27.17&#x02009;&#x000b1;&#x02009;1.36</td></tr><tr><td align="left"><bold>3I</bold></td><td align="center">Cl</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="char" char="&#x000b1;">16.93&#x02009;&#x000b1;&#x02009;0.83</td></tr><tr><td align="left"><bold>3J</bold></td><td align="center">Br</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="char" char="&#x000b1;">15.93&#x02009;&#x000b1;&#x02009;0.80</td></tr><tr><td align="left"><bold>3K</bold></td><td align="center">H</td><td align="center">F</td><td align="center">H</td><td align="center">F</td><td align="center">H</td><td align="char" char="&#x000b1;">14.03&#x02009;&#x000b1;&#x02009;0.70</td></tr><tr><td align="left"><bold>3L</bold></td><td align="center">F</td><td align="center">F</td><td align="center">F</td><td align="center">H</td><td align="center">H</td><td align="char" char="&#x000b1;">7.98&#x02009;&#x000b1;&#x02009;0.40</td></tr></tbody></table></table-wrap></sec><sec id="S0003-S2003-S3002" disp-level="3"><title>Evaluation of STS inhibition in the MCF-7 cell line</title><p>The next step of the biological evaluation was to verify whether the obtained new STS inhibitors based on 6&#x02013;(1-phenyl-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamates <bold>3A-L</bold> are able to inhibit STS activity in the MCF-7 cancer cell line. In the course of our study, we determined the level of STS inhibition in the MCF-7 cells after incubation in the presence of inhibitors at 100, 10, and 1&#x02009;nM concentrations. The summarised results are presented in <xref rid="t0004" ref-type="table">Table 4</xref>. In the course of our research, we found that in the presence of inhibitor at 100&#x02009;nM concentration, the lowest STS activities were measured for derivatives <bold>3K</bold> (5.43% of STS activity) and <bold>3L</bold> (5.29% of STS activity) substituted at R<sub>1</sub>, R<sub>2</sub> or R<sub>3</sub> position with fluorine atoms. These results were comparable with those obtained for the reference compound &#x02013; <italic>Irosustat</italic> (remaining STS activity of 5.72%). In the next step, six of the most promising derivatives <bold>3G-L</bold> were selected and tested at an inhibitor concentration of 10&#x02009;nM. Among these compounds, the highest STS inhibitory activities were observed for the derivatives <bold>3I</bold>, <bold>3K</bold>, and <bold>3L</bold> (remaining STS activity of 42.09%, 42.01% and 27.48%, respectively). As the research showed, the tested compounds showed slightly weaker activity in comparison with <italic>Irosustat</italic> (remaining STS activity of 12.93% at an inhibitor concentration of 10&#x02009;nM). In order to further verify the potential of the new selected compounds, the STS activity was measured in the presence of <bold>3I</bold>, <bold>3K</bold>, and <bold>3L</bold> at the inhibitor concentration of 1&#x02009;nM. For these compounds, an IC<sub>50</sub> parameter was determined as well. The studies showed that the tested compounds based on 6&#x02013;(1-phenyl-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamates <bold>3I</bold>, <bold>3K</bold>, and <bold>3L</bold> found to be very potent STS inhibitors characterised by low IC<sub>50</sub> values of 30.14, 17.02, 15.97&#x02009;nM, respectively (IC<sub>50</sub> parameter determined for <italic>Irosustat</italic> was 1.14&#x02009;nM). The obtained results indicated that 6&#x02013;(1-phenyl-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamates may be very promising in further <italic>in&#x000a0;vivo</italic> studies. Overall, among all the newly prepared compounds, the highest activity was shown by those with fluorine atoms in their structures. We assume that their effectiveness may be influenced by the possibility of electrostatic interactions between fluorine atoms and the Arg98 residue in the STS active site (as suggested in molecular modelling studies) as well as a higher susceptibility of these structures to nucleophilic substitution reaction on the sulphur atom. Moreover, the presence of C-F bonds in the structure of biologically active compounds often affects a number of favourable properties, including metabolic stability, leading to higher therapeutic effectiveness.</p><table-wrap id="t0004" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Remaining STS activity in MCF-7 cells after incubation with compounds <bold>3&#x02009;A-L</bold> and <italic>Irosustat</italic> at 100, 10 and 1&#x02009;nM inhibitor concentrations.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th colspan="10" align="left"><inline-graphic xlink:href="IENZ_A_1858820_ILG0004_B.gif" content-type="black-white"/><hr/></th></tr><tr><th rowspan="2" align="left">No.</th><th rowspan="2" align="center">R<sub>1</sub></th><th rowspan="2" align="center">R<sub>2</sub></th><th rowspan="2" align="center">R<sub>3</sub></th><th rowspan="2" align="center">R<sub>4</sub></th><th rowspan="2" align="center">R<sub>5</sub></th><th colspan="3" align="center">Remaining STS activity [%]<hr/></th><th align="center">&#x000a0;</th></tr><tr><th align="center">100 [nM]</th><th align="center">10 [nM]</th><th align="center">1 [nM]</th><th align="center">IC<sub>50</sub> [nM]</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>3A</bold></td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="char" char="&#x000b1;">15.52&#x02009;&#x000b1;&#x02009;0.78</td><td align="char" char="&#x000b1;">&#x02013;</td><td align="char" char="&#x000b1;">&#x02013;</td><td align="char" char="&#x000b1;">&#x02013;</td></tr><tr><td align="left"><bold>3B</bold></td><td align="center">H</td><td align="center">F</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="char" char="&#x000b1;">12.22&#x02009;&#x000b1;&#x02009;0.61</td><td align="char" char="&#x000b1;">&#x02013;</td><td align="char" char="&#x000b1;">&#x02013;</td><td align="char" char="&#x000b1;">&#x02013;</td></tr><tr><td align="left"><bold>3C</bold></td><td align="center">H</td><td align="center">Cl</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="char" char="&#x000b1;">22.05&#x02009;&#x000b1;&#x02009;1.10</td><td align="char" char="&#x000b1;">&#x02013;</td><td align="char" char="&#x000b1;">&#x02013;</td><td align="char" char="&#x000b1;">&#x02013;</td></tr><tr><td align="left"><bold>3D</bold></td><td align="center">H</td><td align="center">Br</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="char" char="&#x000b1;">20.59&#x02009;&#x000b1;&#x02009;1.03</td><td align="char" char="&#x000b1;">&#x02013;</td><td align="char" char="&#x000b1;">&#x02013;</td><td align="char" char="&#x000b1;">&#x02013;</td></tr><tr><td align="left"><bold>3E</bold></td><td align="center">H</td><td align="center">H</td><td align="center">F</td><td align="center">H</td><td align="center">H</td><td align="char" char="&#x000b1;">11.32&#x02009;&#x000b1;&#x02009;0.57</td><td align="char" char="&#x000b1;">&#x02013;</td><td align="char" char="&#x000b1;">&#x02013;</td><td align="char" char="&#x000b1;">&#x02013;</td></tr><tr><td align="left"><bold>3F</bold></td><td align="center">H</td><td align="center">H</td><td align="center">Cl</td><td align="center">H</td><td align="center">H</td><td align="char" char="&#x000b1;">13.25&#x02009;&#x000b1;&#x02009;0.66</td><td align="char" char="&#x000b1;">&#x02013;</td><td align="char" char="&#x000b1;">&#x02013;</td><td align="char" char="&#x000b1;">&#x02013;</td></tr><tr><td align="left"><bold>3G</bold></td><td align="center">H</td><td align="center">H</td><td align="center">Br</td><td align="center">H</td><td align="center">H</td><td align="char" char="&#x000b1;">8.68&#x02009;&#x000b1;&#x02009;0.43</td><td align="char" char="&#x000b1;">59.86&#x02009;&#x000b1;&#x02009;2.99</td><td align="char" char="&#x000b1;">&#x02013;</td><td align="char" char="&#x000b1;">&#x02013;</td></tr><tr><td align="left"><bold>3H</bold></td><td align="center">F</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="char" char="&#x000b1;">8.80&#x02009;&#x000b1;&#x02009;0.44</td><td align="char" char="&#x000b1;">55.84&#x02009;&#x000b1;&#x02009;2.79</td><td align="char" char="&#x000b1;">&#x02013;</td><td align="char" char="&#x000b1;">&#x02013;</td></tr><tr><td align="left"><bold>3I</bold></td><td align="center">Cl</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="char" char="&#x000b1;">7.44&#x02009;&#x000b1;&#x02009;0.37</td><td align="char" char="&#x000b1;">42.09&#x02009;&#x000b1;&#x02009;2.10</td><td align="char" char="&#x000b1;">84.32&#x02009;&#x000b1;&#x02009;4.22</td><td align="char" char="&#x000b1;">30.14&#x02009;&#x000b1;&#x02009;1.51</td></tr><tr><td align="left"><bold>3J</bold></td><td align="center">Br</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="center">H</td><td align="char" char="&#x000b1;">7.30&#x02009;&#x000b1;&#x02009;0.37</td><td align="char" char="&#x000b1;">59.45&#x02009;&#x000b1;&#x02009;2.97</td><td align="char" char="&#x000b1;">&#x02013;</td><td align="char" char="&#x000b1;">&#x02013;</td></tr><tr><td align="left"><bold>3K</bold></td><td align="center">H</td><td align="center">F</td><td align="center">H</td><td align="center">F</td><td align="center">H</td><td align="char" char="&#x000b1;">5.43&#x02009;&#x000b1;&#x02009;0.27</td><td align="char" char="&#x000b1;">42.01&#x02009;&#x000b1;&#x02009;2.10</td><td align="char" char="&#x000b1;">79.30&#x02009;&#x000b1;&#x02009;3.96</td><td align="char" char="&#x000b1;">17.02&#x02009;&#x000b1;&#x02009;0.85</td></tr><tr><td align="left"><bold>3L</bold></td><td align="center">F</td><td align="center">F</td><td align="center">F</td><td align="center">H</td><td align="center">H</td><td align="char" char="&#x000b1;">5.29&#x02009;&#x000b1;&#x02009;0.26</td><td align="char" char="&#x000b1;">27.48&#x02009;&#x000b1;&#x02009;1.37</td><td align="char" char="&#x000b1;">99.00&#x02009;&#x000b1;&#x02009;4.95</td><td align="char" char="&#x000b1;"><bold>15.97&#x02009;</bold>&#x000b1;<bold>&#x02009;0.80</bold></td></tr><tr><td align="left"><italic toggle="yes">Irosustat</italic></td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="char" char="&#x000b1;">5.72&#x02009;&#x000b1;&#x02009;0.29</td><td align="char" char="&#x000b1;">12.93&#x02009;&#x000b1;&#x02009;0.65</td><td align="char" char="&#x000b1;">16.83&#x02009;&#x000b1;&#x02009;0.84</td><td align="char" char="&#x000b1;">1.14&#x02009;&#x000b1;&#x02009;0.06</td></tr></tbody></table></table-wrap></sec></sec></sec><sec sec-type="conclusions" id="S0004" disp-level="1"><title>Conclusions</title><p>In the present work, we described our research on molecular modelling, synthesis, and biological evaluation of 6&#x02013;(1-phenyl-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate derivatives <bold>3A-L</bold> as new very potent STS inhibitors. Screening enzymatic assay, performed using the STS enzyme isolated from the human placenta indicated that all of the newly synthesised inhibitors <bold>3A-L</bold> were able to effectively inhibit the action of STS. Among them, the highest inhibitory activity was exhibited by compound <bold>3L</bold> containing three fluorine atoms in its structure (remaining STS activity of 7.98%). In the course of the cell line experiment, we observed the highest inhibition of STS in the presence of 6&#x02013;(1-phenyl-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamates <bold>3I</bold>, <bold>3K</bold>, and <bold>3L</bold> characterised by low IC<sub>50</sub> values of 30.14, 17.02, 15.97&#x02009;nM, respectively (IC<sub>50</sub> value determined for <italic>Irosustat</italic> was 1.14&#x02009;nM). The presented results showed that 6&#x02013;(1-phenyl-1<italic>H</italic>-1,2,3-triazol-4-yl)naphthalen-2-yl sulphamate derivatives may be very promising anticancer agents and their therapeutic potential should be confirmed in further <italic>in&#x000a0;vivo</italic> studies. Furthermore, the data of enzymatic and cell line experiments suggested that the possibility of creating electrostatic interactions between the fluorine atoms of compounds and the Arg98 residue in the active site of STS as well as a higher susceptibility to nucleophilic substitution reaction on the sulphur atom could be critical for their inhibitory effects.</p></sec></body><back><sec id="S0005" disp-level="1" sec-type="COI-statement"><title>Disclosure statement</title><p>The authors report no conflict of interest.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="web"><person-group person-group-type="author"><collab>IARC: CANCER FACT SHEETS [Internet]</collab></person-group> Lyon (France): International Agency for Research on Cancer. Available from: <ext-link ext-link-type="uri" xlink:href="https://gco.iarc.fr/today/factsheets-cancers">https://gco.iarc.fr/today/factsheets-cancers</ext-link> [last accessed 10 May 2020].</mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="web"><person-group person-group-type="author"><collab>NCI [Internet]</collab></person-group> Maryland (U.S.): National Cancer Institiute. Available from: <ext-link ext-link-type="uri" xlink:href="https://seer.cancer.gov/statfacts/html/breast.html">https://seer.cancer.gov/statfacts/html/breast.html</ext-link> [last accessed on 10 May 2020].</mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasqualini</surname><given-names>JR.</given-names></name></person-group>
<article-title>The selective estrogen enzyme modulators in breast cancer: a review</article-title>. <source>Biochim Biophys Acta Rev</source>
<year>2004</year>;<volume>1654</volume>:<fpage>123</fpage>&#x02013;<lpage>43</lpage>.</mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Purohit</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Woo</surname><given-names>LWL</given-names></name>, <name name-style="western"><surname>Potter</surname><given-names>BVL.</given-names></name></person-group>
<article-title>Steroid sulfatase: a pivotal player in estrogen synthesis and metabolism</article-title>. <source>Mol Cell Endocrinol</source>
<year>2011</year>;<volume>340</volume>:<fpage>154</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">21693170</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>D</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Sulfatase inhibitors for recidivist breast cancer treatment: a chemical review</article-title>. <source>Eur J Med Chem</source>
<year>2016</year>;<volume>114</volume>:<fpage>170</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">26974384</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reed</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Purohit</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Woo</surname><given-names>LWL</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Steroid sulfatase: molecular biology, regulation, and inhibition</article-title>. <source>Endocr Rev</source>
<year>2005</year>;<volume>26</volume>:<fpage>171</fpage>&#x02013;<lpage>202</lpage>.<pub-id pub-id-type="pmid">15561802</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zaraei</surname><given-names>S-O</given-names></name>, <name name-style="western"><surname>Abduelkarem</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Anbar</surname><given-names>HS</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Sulfamates in drug design and discovery: pre-clinical and clinical investigations</article-title>. <source>Eur J Med Chem</source>
<year>2019</year>;<volume>179</volume>:<fpage>257</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">31255926</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ring</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Dowsett</surname><given-names>M.</given-names></name></person-group>
<article-title>Mechanisms of tamoxifen resistance</article-title>. <source>Endocr Relat Cancer</source>
<year>2004</year>;<volume>11</volume>:<fpage>643</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">15613444</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foster</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Chander</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Newman</surname><given-names>SP</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor</article-title>. <source>Clin Cancer Res</source>
<year>2008</year>;<volume>14</volume>:<fpage>6469</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">18927286</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dixon</surname><given-names>JM.</given-names></name></person-group>
<article-title>Endocrine resistance in breast cancer</article-title>. <source>New J Sci</source>
<year>2014</year>;<volume>2014</volume>:<fpage>1</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foster</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Reed</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Purohit</surname><given-names>MJ.</given-names></name></person-group>
<article-title>Recent developments of steroid sulfatase inhibitors as anti-cancer agents</article-title>. <source>Anticancer Agents Med Chem</source>
<year>2008</year>;<volume>8</volume>:<fpage>732</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">18855575</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chanplakorn</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Chanplakorn</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Suzuki</surname><given-names>T</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Increased estrogen sulfatase (STS) and 17&#x003b2;-hydroxysteroid dehydrogenase type 1(17&#x003b2;-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients</article-title>. <source>Breast Cancer Res Treat</source>
<year>2010</year>;<volume>120</volume>:<fpage>639</fpage>&#x02013;<lpage>48</lpage>.<pub-id pub-id-type="pmid">20151319</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Da&#x0015b;ko</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Demkowicz</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Biernacki</surname><given-names>K</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Recent progress in the development of steroid sulphatase inhibitors - examples of the novel and most promising compounds from the last decade</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2020</year>;<volume>35</volume>:<fpage>1163</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">32363947</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malini</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Purohit</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ganeshapillai</surname><given-names>D</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Inhibition of steroid sulphatase activity by tricyclic coumarin sulphamates</article-title>. <source>J Steroid Biochem Mol Biol</source>
<year>2000</year>;<volume>75</volume>:<fpage>253</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">11282279</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woo</surname><given-names>LWL</given-names></name>, <name name-style="western"><surname>Purohit</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Malini</surname><given-names>B</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates</article-title>. <source>Chem Biol</source>
<year>2000</year>;<volume>7</volume>:<fpage>773</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">11033081</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stanway</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Purohit</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Woo</surname><given-names>LWL</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor</article-title>. <source>Clin Cancer Res</source>
<year>2006</year>;<volume>12</volume>:<fpage>1585</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">16533785</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palmieri</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Januszewski</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Stanway</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Coombes</surname><given-names>RC.</given-names></name></person-group>
<article-title>Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer</article-title>. <source>Expert Rev Anticancer Ther</source>
<year>2011</year>;<volume>11</volume>:<fpage>179</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">21342037</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palmieri</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Stein</surname><given-names>RC</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>X</given-names></name></person-group>, <person-group person-group-type="editor"><etal>et&#x000a0;al.</etal></person-group>
<article-title>IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients</article-title>. <source>Breast Cancer Res Treat</source>
<year>2017</year>;<volume>165</volume>:<fpage>343</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">28612226</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palmieri</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Stein</surname><given-names>RC</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>X</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A Phase II study to assess the safety and efficacy of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER positive locally advanced or metastatic breast cancer patients (IRIS) &#x02013; trial results</article-title>. <source>J Clin Oncol</source>
<year>2016</year>;<volume>34</volume>:<fpage>549</fpage>.</mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palmieri</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Szydlo</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Miller</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer</article-title>. <source>Breast Cancer Res Treat</source>
<year>2017</year>;<volume>166</volume>:<fpage>527</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">28795252</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Potter</surname><given-names>BVL.</given-names></name></person-group>
<article-title>Sulfation pathways: steroid sulphatase inhibition via aryl sulphamates: clinical progress, mechanism and future prospects</article-title>. <source>J Mol Endocrinol</source>
<year>2018</year>;<volume>61</volume>:<fpage>T233</fpage>&#x02013;<lpage>T252</lpage>.<pub-id pub-id-type="pmid">29618488</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Da&#x0015b;ko</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Demkowicz</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Rachon</surname><given-names>J</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>New potent STS inhibitors based on fluorinated 4-(1-phenyl-1<italic>H</italic>-[1,2,3]triazol-4-yl)-phenyl sulfamates</article-title>. <source>J Asian Nat Prod Res</source>
<year>2020</year>;<volume>22</volume>:<fpage>1037</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">31773975</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bozorov</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Aisa</surname><given-names>HA.</given-names></name></person-group>
<article-title>1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: a recent overview</article-title>. <source>Bioorg Med Chem</source>
<year>2019</year>;<volume>27</volume>:<fpage>3511</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">31300317</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kommidi</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Nurili</surname><given-names>F</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title><sup>18</sup>F-positron emitting/trimethine cyanine-fluorescent contrast for image-guided prostate cancer management</article-title>. <source>J Med Chem</source>
<year>2018</year>;<volume>61</volume>:<fpage>4256</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">29676909</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Radiosynthesis and biological evaluation of <sup>18</sup>F-labeled 4-anilinoquinazoline derivative (<sup>18</sup>F-FEA-Erlotinib) as a potential EGFR PET agent</article-title>. <source>Bioorganic Med Chem Lett</source>
<year>2018</year>;<volume>28</volume>:<fpage>1143</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Stapleton</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Haider</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Healy</surname><given-names>J.</given-names></name></person-group>
<article-title>Boronic acid inhibitors of the class A &#x003b2;-lactamase KPC-2</article-title>. <source>Bioorg Med Chem</source>
<year>2018</year>;<volume>26</volume>:<fpage>2921</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">29784271</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopes</surname><given-names>SMM</given-names></name>, <name name-style="western"><surname>Novais</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Costa</surname><given-names>DCS</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Hetero-Diels-Alder reactions of novel 3-triazolyl-nitrosoalkenes as an approach to functionalized 1,2,3-triazoles with antibacterial profile</article-title>. <source>Eur J Med Chem</source>
<year>2018</year>;<volume>143</volume>:<fpage>1010</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">29232578</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Batra</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Rajendran</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Agarwal</surname><given-names>D</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and antimalarial evaluation of [1,2,3]-Triazole-Tethered Sulfonamide-Berberine Hybrids</article-title>. <source>ChemistrySelect</source>
<year>2018</year>;<volume>3</volume>:<fpage>9790</fpage>&#x02013;<lpage>3</lpage>.</mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="web"><person-group person-group-type="author"><collab>HyperChem(TM) Professional 7.51, Hypercube, Inc., 1115 NW 4th Street</collab></person-group>, Gainesville, Florida, USA.&#x000a0;Available from: <ext-link ext-link-type="uri" xlink:href="http://www.hyper.com">www.hyper.com</ext-link></mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hocquet</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Langg&#x000e5;rd</surname><given-names>M.</given-names></name></person-group>
<article-title>An evaluation of the MM&#x02009;+&#x02009;force field</article-title>. <source>J Mol Model</source>
<year>1998</year>;<volume>4</volume>:<fpage>94</fpage>&#x02013;<lpage>122</lpage>.</mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Schr&#x000f6;dinger Release 2020-3: Maestro</collab></person-group>, <person-group person-group-type="editor"><collab>Schr&#x000f6;dinger</collab></person-group>, LLC, New York, NY, <year>2020</year>.</mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaminski</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Duffy</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Matsui</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Jorgensen</surname><given-names>W.</given-names></name></person-group>
<article-title>Free energies of hydration and pure liquid properties of hydrocarbons from the OPLS All-Atom Model</article-title>. <source>J Phys Chem</source>
<year>1994</year>;<volume>98</volume>:<fpage>13077</fpage>&#x02013;<lpage>82</lpage>.</mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trott</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Olson</surname><given-names>AJ.</given-names></name></person-group>
<article-title>Autodock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</article-title>. <source>J Comput Chem</source>
<year>2010</year>;<volume>31</volume>:<fpage>455</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">19499576</pub-id></mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Humphrey</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Dalke</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Schulten</surname><given-names>K.</given-names></name></person-group>
<article-title>VMD: visual molecular dynamics</article-title>. <source>J Mol Graph</source>
<year>1996</year>;<volume>14</volume>:<fpage>33</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">8744570</pub-id></mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>BIOVIA</collab></person-group>, Dassault Syst&#x000e8;mes. Discovery Studio Visualizer, v20. 1. 0. 19295. San Diego: Dassault Syst&#x000e8;mes; <year>2020</year></mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hernandez-Guzman</surname><given-names>FG</given-names></name>, <name name-style="western"><surname>Higashiyama</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Osawa</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Ghosh</surname><given-names>D.</given-names></name></person-group>
<article-title>Purification, characterization and crystallization of human placental estrone/dehydroepiandrosterone sulfatase, a membrane-bound enzyme of the endoplasmic reticulum</article-title>. <source>J Steroid Biochem Mol Biol</source>
<year>2001</year>;<volume>78</volume>:<fpage>441</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">11738554</pub-id></mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Purohit</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Williams</surname><given-names>GJ</given-names></name>, <name name-style="western"><surname>Howarth</surname><given-names>NM</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Inactivation of steroid sulfatase by an active site-directed inhibitor, estrone-3-O-sulfamate</article-title>. <source>Biochemistry</source>
<year>1995</year>;<volume>34</volume>:<fpage>11508</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">7547880</pub-id></mixed-citation></ref></ref-list></back></article>